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and Bovine Viral  Diarrhea Virus (BVDV),  are known to create  havoc  for  humans and animal  health alike.  
Although vaccines have helped to control several of the most important viral pathogens, there is currently little 
prospect of an effective vaccine for either HCV or HIV. These pathogens infect ~170 million and ~40 million 
people   worldwide,   respectively,   hastening   the   need   for   effective   antiviral   drugs.   Likewise   BVDV   infects  















of  virus comes with i)­   the knowledge of  pathological,  cellular  and molecular  mechanism involved  in the 
disease;   and   ii)­   the   identification   of  macromolecule   (i.e   possible   drug   target)   involved   in   pathological 
pathways, their 3D structures and their functions. The biological activity of drug molecules is dependent on  
















therapeutic   intervention,  but  also  because  of  advances   in  algorithms,   representations,   and  mathematical 
procedures for studying such processes.














































































































































































Figure17:Model   illustrating   the  putative  mechanism  of  BVDV  RdRp   resistance   against   227G.  A   cartoon  
representation of BVDV RdRp is shown with the thumb (blue), finger (green) and palm (pink) domain.








Figure2:   Evolution   of   the   center   of  mass   of   227G   in   (a)   COMPLEX   and   (b)   COMPLEXm  during   the    
metadynamics simulations of the undocking process. 








Figure1:Cartoon representation of  HIV­RT.  Two subunits  P66(colored according  to   the  subdomains)  and  
P51(white) are depicted here.  Finger   is   represented   in   blue,   Palm   in   red,  Thumb   in   green,   the  





compounds.  B)    Docked  structures  of   the  DABO compound  into   the  NNRTI  binding  cavity.  The  




color   spirals.  B)  Ligand­residue   interaction  energies   in  kcal/mol   for   the   residues   that  contribute  














conserved   structural   features   of   HIVRT,   the   Primer   grip   and   catalytic   triad(YMDD  motif).   A)  
Normalized histogram of the distances are repersented. The red and purple dotted line indicate the 
minimum distances between  the beta sheets in  1DLO( without substrate) and 1RTD (with substrate) 





Table1:Approved   antiviral   drugs   against  HCV.   Adapted   from:  HCV   Advocate;   July   24,   2010;Hepatitis   C  
treatment in current clinical development; Alan Franciscus.
Table2:Approved antiretroviral drugs. Adapted from: Drugs Used in the Treatment of HIV Infection, U.S. FDA, 
























The history  of  antiviral  drug development has   taken numerous  circuitous   routes   from the  discovery  and  
development   of   the   first   US   Food   and   Drug   Administration   (FDA)   approved   antiviral   agent,   5­iodo­2 
­deoxyuridine (Idoxuridine) by William H. Prusoff [1,2], to the development of simplified but powerful triple 
combinations   for  HIV   such   as   Atripla   and  Trizivir   [3,4,5].  Many   challenges   are   encountered   during   the 
development of  antiviral  agents,   including adverse events  and  the development of  drug  resistant  viruses,  
which necessitate chemists, biologists, and pharmacologists to develop improved, more potent, and less toxic  
medicines with “high genetic barrier.” Although there are major differences among viruses, specific virological, 











Why  BVDV:  Likewise,   Bovine   viral   diarrhea   virus   (BVDV),   is   a  major   viral  pathogen   in   cattle   and  other  
ruminants[12].  Infection  of   cattle  with  BVDV  can   result   in   a  wide   assortment   of   disease  manifestations 
including resorption, mummification, or  abortion of  the dead fetus while those fetuses who survive early  
infection may be malformed or blind, may have skeletal defects, respiratory problems, underdeveloped brain 
or weak immune system[13].  This results in a high mortality rate in cattle as well as cause huge economic 























antivirals,  due to the propping up of  resistance mutations were able to skirt  every drug from the biotech  
arsenal.  The capacity of the viral pathogen for rapid evolution is one of the main reason for the need of further  
refinement and development of antiviral drug design.
Figure1:  Global  variations   in  age  adjusted   incidence  rates  of   liver  cancer,  prevalence of  chronic  HCV  infection  and chronic  HBV  


















(NNIs),  which are a diverse group of compounds that bind to a allosteric cavity,  inducing conformational  
changes that inhibits the function of RT and RdRp.[23,24]. These NIs and NNIs have become the cornerstone 
for successful treatment of viral infection. 





















been  applied  on   the   three  protein   systems   to   answer   fundamental  questions  of  drug­protein  molecular  
recognition, drug resistance, drug inhibition, thereby providing clues for improvement of antivirals.
In the last twenty­five years the advances in biological sciences, including many experimental techniques such  
as   quantitative   structure   activity   relationship,   high­throughput   screening   (mass   spectrometry)   for 
identification  of  new   lead   compounds,  replicon,   and  cell   based  assays   to  predict   toxicity   and   resistance 
aspects, pharmacokinetic and pharmacodynamic aspects as radioactive enzymatic assays and fluorescence 
based assays. This plethora of methods are used to identify, evaluate and screen antiviral compounds against 






Figure2:  Top 10 Countries,  Adult  HIV Prevalence Rate,  2009.  Note:  Data  are estimate.  Prevalence rates   include adults  aged 15­49. 
Adapted from : Kaiser Family Foundation, www.GlobalHealthFacts.org, based on UNAIDS, Report on the Global AIDS Epidemic, 2010. 
Figure3:  A global  View of HIV infection, 33.3 million people [31.4­35.3]   living with HIV,  2009.  Adapted From: Joint United Nations 
Programme on HIV/AIDS(UNAIDS) and World Health Organization (WHO) 2009 AIDS epidemic update
16
However,   the   amino  acid   sequence  of  proteins   yields  only   limited   information   about   the   structure   and 
function of biological macromolecules. Processes such as molecular recognition with respect to protein­ligand 
interaction,   catalytic   function   of   enzymes,   gating  mechanisms   in   ion   channels,   conformational   change 
required by the protein to accommodate the ligands into binding site, mechanisms of inhibition and drug 
resistance, change in the protein dynamics on introduction of resistance mutations and understanding the 
dynamic  behavior  of  proteins   at  different   timescales,   from  fast   internal  motions   to   slow conformational 
changes,   or   even  protein   folding  processes   the   assembly,   and   signal   transduction   or   immune   response  
pathways cannot be explained by these sequences.
To bridge this gap the development in the field of computational biochemistry is tremendously contributing 













































protein–ligand   complexes.  The   strength   of   this   combination   lies   in   their   complementary   strengths   and 
weaknesses.  One the one hand,  docking techniques are  used to explore the vast  conformational  space of 
ligands in a short time, allowing the scrutiny of large libraries of drug­like compounds at a reasonable cost.  
The major  drawbacks are   the  lack,  or  poor ﬂexibility  of   the protein,  which  is  not  permitted  to  adjust   its  
















receptors.  The  distribution  and  stability  of   each  conformational   state  of   the  protein  will  depend  on   the 
















Some of   the  most   successful  docking   schemes  are  based  on  a  combination  of   the   two  approaches   in  a 
multistage process, where fast methods are used to screen a large number of ligands and accurate methods to 
refine the docking geometry and binding energy for the most promising candidates. The efficiency of the  


























obtain   the  correct  docking  pose  without  any  prior  knowledge  of  a  putative  binding   site.  The   theoretical  
prediction of  binding affinities   is  one of   the most   important  problems  in  computational  biochemistry.   It 
complements  experimental  analysis  and  adds  molecular   insight   to   the  macroscopic  properties  measured 




accuracy   of   its   application   has   varied.   The   most   rigorous   methods   involve   alchemical   or   structural  
transformations   such   as   free   energy  perturbation   and   thermodynamic   integration[70,71].   End­point   free 
energy methods, such as the Molecular Mechanics Poisson­Boltzmann Surface Area (MM­PBSA) model, have 
received  much   attention   and  widespread   application   in   recent   literature.  These  methods   benefit   from 












binders.  This  contrasts  with   the   relatively   large  number  of   studies  on NNIs   ligands  on  HCV RdRp.  More 









of   compounds   found   active   against   BVDV,   HCV   and   HIV.   The   molecules   belong   to   Benzimidazole,  
Imidazoquinoline, Pyridoxoquinoline, Phenanthroline and DABO are used as a ligand to understand protein­






















aqueous   solution.  Then,   we   selected   representative   equilibrium   conformations   by   performing   a   cluster 
analysis,  and ran docking calculations of 277G on representative of the 5 most populated clusters of each  








target of our  lead benzimidazole compound 227G. Here,  we performed a multidisciplinary computational  












































of   the   binding   free   energies   linearly   correlate   very   well   with   those   derived   from   the   corresponding 
experimental  data,  suggesting that  the newly proposed protocol  may be used as  generalized approach to 
predict drug resistance associated with mutation I261M. Because it is essentially important for understanding  
the structure­resistance correlation and for structure based drug design to develop an effective computational  








some   local   transient  binding   site,  which  was  barely  noticed  by   x­ray   and  other   techniques.  The 


















The  present   calculations  provide  a  validation  of   the  combination  of  docking,  MD as  a  powerful   tool   in  













Chapter1:  Different  binding  sites  of   the  benzimidazole  compound  227G on  HCV and 
BVDV RdRps revealed by MD simulations.
Key­abstract















































In   silico  Antiviral  Activity  Against  Flaviviridae  Family  of  Three  New Classes  of  Virus­
Encoded RNA­Dependent RNA Polymerase (RdRp) Inhibitors.
Key­abstract:
In   this   preliminary   study   three   new   classes   of   RNA­dependent   RNA   polymerase   (RdRp)   of   Flaviviridae 
inhibitors, the linear N­tricyclic systems derived by condensation of the quinoline nucleus with 1,2,3­triazole,  
imidazole   or   pyrazine   (obtaining   triazolo[4,5­g]quinolines,   imidazo[4,5­g]quinolines   and   pyrido[2,3­







IC50  =  of  0.06  µM. Herein,  we  have  utilized   several  biophysical   computational  approaches,   ranging   from 
Docking, standard molecular dynamics and metadynamics , in order to predict the binding site, to identify key  
determinants of  ligand binding,  the energetics of unbinding as well  as the escape mechanism of the lead  
compounds PS999 and PS1036 in BVDV RdRp. MM­PBSA techniques were used to calculate the binding free  








1. Identified   Binding   cavity   for   leads   belonging   to   pyridoxoquinoxaline(PS1036)   as   well   as 
imidazoquinoline(PS999) derivative in BVDV RdRp. The choice for the study of the leads was based on  
the knowledge of the resistant mutations against these compound.






























(C) benzothiadiazine    inhibitors was examined for the binding of the compounds.  We then used all  atom 
standard  molecular   dynamics   (MD)   simulations   to   investigate   the  most   probable   binding   site   for   the 
compounds in both complexes; dissociation was observed in two out of the three cavities under investigation. 





1. A blind docking procedure was applied  in all   four well  known binding sites  reported for  different 
classes of compounds in HCV RdRp, to obtained the most prominent binding pocket for compound 
PS1097 (Pyridoxiquinoline) and compound PS1126 (Imidazoquinoline).











1. We   identified   probable   binding   cavity   for   NNIs   belonging   to   three   different   classes 
Pyridoxoquinoxaline   ,   Imidazoquinoxaline   and   phenonthrolines.   This   was   an   encouraging 



















ASCC16912 Imido PS11262.0 MC13460.005
Imido PS9990.6 Pyrido PS10970.6 MC11950.05















• Binding mode validation 
• Binding Affinity
Metadynamics















































































intramembrane arrow, cleavage by the signal  peptide peptidase.  The transmembrane domains of  E1 and E2 are shown after  signal­
































Before Tat  is  present,  a  small  number of RNA transcripts will  be made, which allow the Tat protein to be  








viral   particles.   In   the   absence   of  Vif,   the   produced   viral   particles   are   defective,   while   the   cell­to­cell  
transmission of virus is not affected significantly. Found in almost all lentiviruses, Vif is a cytoplasmic protein,  















lentiviruses.  Other   forms   of  Nef   are   known,   including   nonmyristoylated   variants.  Nef   is   predominantly  




























the   presence   of   two   extended   loops,   the   fingertips,   that   connect   the   fingers   and   thumb   domains   and 
completely encircle the active site cavity, to which the RNA template and the nucleoside triphosphate (NTP) 
substrates have access through two positively charged tunnels [85]. 
The  palm  sub­domain  (residue 188  to 227,  287 to  370)  constitutes   the catalytic   site  of   the molecule  and 
contains the residues responsible for the nucleotidyl transfer reaction within the D­(X)4­D and the GDD motif.  












structure are a  ­hairpinβ  ( ­loop), protruding from the thumb into the active site, and a β C­ terminal region, 
located immediately before the transmembrane domain, that folds from the surface of the thumb towards the  
active site and establishes a series of hydrophobic interactions with a shallow pocket comprised between the  

















channel may be limited  [94,95]. The remainder of the finger domain is comprised of a  ­strand­rich region ( ­β β
fingers) and an  ­helix­rich region ( ­fingers) close to the palm domain. Although there is   little sequenceα α  
identity,   the   topology   of   the   fingers   domain,   excluding   the   finger­tips,   is   similar   to   that   of   other   viral  
polymerases,  making  possible   the structural  alignment  of   the  BVDV,  HCV,  calicivirus,  and  6  polymeraseφ  




sheet flanked by two  ­helices on one side and an additional  ­helix on the other side of the  ­sheet, nestedα α β  
between the palm and thumb domains. Compared to HCV polymerase, BVDV polymerase has a small  ­helixα  






eight  ­helices and five  ­strands and is larger than the thumb domain of other viral RdRps  Although there isα β  
some structural similarity between the HCV and BVDV thumb domains, the overall topology is rather different. 
The BVDV polymerase thumb domain possesses a structural element (‘‘the  ­thumb region’’) in which two  ­β β
strands  and  their  connecting  loops   form a  layer   that  occludes  the active  site  cavity.  The  ­thumb regionβ  










interacting with the fingertip region and thumb domain through a  ­hairpin motif. The  ­hairpin motif pointsβ β  
toward the template channel and partially occludes the channel entrance, possibly explaining why some N­
terminal   truncated  proteins   have   greater   polymerase   activity   than  wild   type   [102].  The   entrance   to   the 
template­binding channel created by the hairpin motif of the N­terminal domain is highly positively charged. 
An equivalent positively charged surface at the entrance to the channel was found in  6 polymerase, where itφ  








































virus   replication.   Upon   entry   into   the   cells,   nucleoside   analogues   are   first   converted   to   nucleotide 
triphosphates   (NTP).   The   unnatural   nucleoside   inhibitors   can   serve   as   competitive   substrates   for   the 
polymerase and can be incorporated into the nascent chain by the viral polymerase. This incorporation can  





reported   to   inhibit   the  RdRp enzymatic  activity  and  block  HCV  replication   in   the   replicon  systems.  The 
nucleoside analogues, inhibiting NS5B polymerase activity, have mostly 2′­methylribose structures and  act  as 
chain terminator [114,115]. Chain terminators have proven to be effective against viral DNA polymerases, and 
a  number  of   these  compounds  have  been  approved   for   treatment  of  HIV  and  hepatitis  B.      Nucleoside 
inhibitors are less prone to drug resistance induced by mutations than non­nucleoside inhibitors because they 
bind to the enzyme’s active site, which is more conserved and less genetically variable than the allosteric (non­
catalytic)   sites  bound by non­nucleosides.  Anyway mutation may not  be  the only  resistance  mechanism. 










Later,  a replicon cell   lines­based assay revealed it  to be effective against  HCV. NM 283 is  effective against  
replicons originating from different HCV strains. Replicons resistant to 2’­C­methylcytidine contain the S282T 





Apart from NM283 other 2 ­methyl nucleosides that selectively inhibit of HCV replication are 2 ­O­methyl­′ ′





Lastly, RG7128 (Roche/Pharmasset),  a 2 ­modified nucleo­side analogue, has recently entered early clinical′  
trials. RG7128 is an oral prodrug of 2 ­deoxy­2 ­fluoro­2 ­C­methyl­cytidine, a pyrimidine nucleoside analogue′ ′ ′  
that  was  shown  to  act  as  a  non­obligate  chain   terminator  of   the  NS5B  polymerase  activity   [123]  and   to 
efficiently inhibit the replication of HCV RNA in hepatoma cell lines[Table 1] [124]. 






Non­nucleoside   inhibitors   are   the  most  diverse  of   the   known  HCV  NS5B   inhibitors.  They   act  mostly   as  
allosteric inhibitors and interfere with the conformational transition during the initiation of RNA synthesis  
[126]. In fact,  besides the active site, the X­ray derived co­crystal structures of compounds bound to NS5B 
revealed  distinct   allosteric   regulatory   sites   that   are   located  distant   to   the   active   site   and  are   targets   for  
developing antiviral  agents.  Accordingly,  compounds   that   interact  either  with   the RdRp active  site  or   the 






















IDX375 Polymerase Inhibitor Idenix Phase I
ABT­072 Polymerase Inhibitor Abbott Phase I
MK­3281 Polymerase Inhibitor Merck Phase I
PSI­7851 Polymerase Inhibitor Pharmasset Phase I
ABT­333 Polymerase Inhibitor Abbott Phase I






RG7128 Polymerase Inhibitor Pharmasset/Genentech Phase I
VX­222 Polymerase Inhibitor Vertex Phase II




GS 9190 Polymerase Inhibitor Gilead Phase II
VX­759 Polymerase Inhibitor Vertex Phase II




Several   classes  of   structurally  distinct  NNIs  of   the  HCV  RdRp  have  been   identified   and  disclosed;   these 














containing   heterocycles,   by   extending   the   original   derivatives   to   topologically   related   scaffolds   and 
















Thiophene   and   Benzimidazole   derivatives.   Cross­resistance   studies   and   synergistic   inhibition   of   HCV 
polymerase, by combination of a Benzimidazole and a Benzothiadiazine, further confirmed that these two 
structurally distinct classes of inhibitors had non­overlapping binding sites and thus acted with different mode 
of  action.  Heterocyclic Benzo­1,2,4­thiadiazine derivatives are specific  inhibitors  of RNA synthesis   in HCV 
replicon   systems   [131].   GlaxoSmithKline   (formerly   SmithKline   Beecham)   disclosed   a   novel   class   of 
Benzothiadiazine   derivatives,   from  which   a   representative   compound   displayed   good   potency   both   in 























least   eight   antiviral   drugs   in   clinical   development.  The  disappointments   are  not   new:   drugs   specifically 
targeting the hepatitis C virus have been in the works since the early 1990s, but no compound of this kind has  
yet   advanced   to   phase   3   trials.  Four   of   the   failed   drugs   were   inhibitors   of   NS5B   RNA   polymerase. 




that   are   known   to   have   entered   clinical   trials,   several   other  NNIs   of  HCV   are   in   advanced   preclinical  
development and early results for the newer polymerase inhibitors look promising. A series of  , ­diketoacidα γ  
compounds, as inhibitor of HCV polymerase, has been identified. Further optimization led to identification of  
a   potent   HCV  NS5B   polymerase   inhibitor,   with   an   EC50  of   45nM.  Compounds   of   dihydroxypyrimidine 
carboxylic   acid   class   are  believed   to   chelate   the   two   catalytic  Mg2+  ions   in   the   active   site   as  diketoacid 
compounds. However, no data of in vivo activity for the pyrophosphate mimics are available and the high ionic 
nature of these compounds may raise concerns, such as low bioavailability and toxicity. The binding sites for 
(2s)­2­[(2,4­dichloro­benzoyl)­(3­trifluoromethylbenzyl)­amino]­3­phenyl­propionic   acid   and   (2s)­2­[(5­
Benzofuran­2­ylthiophen­2­ylmethyl)­(2,4­dichlorobenzoyl)­amino]­3­phenylpropionic   acid   are   located   in 
the   thumb   subdomain   35  Å   far   from   the   active   site.   A   benzimidazole   inhibitor   and  N,N  disubstituted 
phenylalanine inhibitor also induced an allosteric interaction [106]. There are 3 classes of inhibitors that bind  
to   a   pocket   in   the   thumb  domain.   Phene   2­carboxylic   acids,   phenylalanine  derivatives   and   cyclopentyl  






be useful  as  anticoagulant,  antibacterial,  anti­inflammatory,  anticancer and anti­HIV agents.  Very  few are 
reported   to   be   able   to   counteract   HCV.   Only   some   coumarin   derivatives   like   Osthole   (7­methoxy­8­
prenylcoumarin) is capable of inhibiting HCV replication and/or proliferation. In particular, Osthole is able to  
counteract the progression of hepatitis C into hepatocarcinoma.  Since the great variability of pharmacological 
response   of   coumarins   is   connected   to   large  modification  of   their   substituents,  Mazzei   and   co­workers 
(Department   of   Pharmaceutical   Sciences,  Genova,   Italy)   found   interesting   to   synthesize   some   coumarin 
Mannich bases in order to examine their ability to inhibit HCV replication.  This idea proved to be a winning 








In  a   journey  of  25  years,  HIV­1,   the   retrovirus   responsible   for   the  acquired  immunodeﬁciency  syndrome 
(AIDS), has gone from being an “inherently untreatable” infectious agent to one eminently susceptible to a  









first   proof   of   concept   that   the   replication   of   HIV   could   be   controlled   by   chemotherapy   and   thereby 
establishing   the   foundation   of   antiretroviral   drug   discovery   research   [150].  Thus,   AZT   became   the   first  
nucleoside HIV reverse transcriptase inhibitor (NRTI).  Over the course of  25 years that followed after  this 





Members  of   the  of  NRTIs  were   eventually   joined  by  nonnucleoside  RT   inhibitors   (NNRTIs),  which  were  
discovered in 1990, and interact with an allosteric binding site on HIV­1 reverse transcriptase that becomes 
exposed  upon  ligand  binding[151].  NNRTIs  are  a  key  part  of   typical  HAART  regimes   for   treatment­naive  















1/AIDS   is   both   cause   and   consequence.  Many   challenges   remain,   including  1)   the   life­long  duration  of 
therapy; 2) the ultimate role of pre­exposure prophylaxis (PrEP); 3) the cardiometabolic side­effects or other  
toxicities   of   long­term   therapy;   4)   the   emergence   of   drug­resistance   and   viral   genetic   diversity   (non­B 
subtypes); 5) the specter of new cross­species transmissions from established retroviral reservoirs in apes and 
Old World monkeys; and 6) the continued pace of new HIV­1 infections in many parts of the world. All of these  
factors  make   refining   current   therapies   and   developing   new   therapeutic   paradigms   essential   priorities.  
Fortunately, there are exciting new insights into the biology of HIV­1, its interaction with cellular resistance  
factors,  and  novel  points  of  attack   for   future   therapies.  The  current  science  will   lead   to  new therapeutic 
strategies with far­reaching implications in the HIV­1/AIDS pandemic[153,154]
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M E T H O D S
1.1 docking
Molecular docking is a multidimensional optimization problem,
requiring efficient samplaing across the entire space of positional,
orientational, and confermational possibilities available to both
a receptor and a ligand it recognizes. Recent flexible docking
studies and the results from the docking section of the critical
assessment of protein.Structure (CASP2) prediction contest [14]
suggest that a suitable combination of homology modeling, dock-
ing strategies and experimental studies can be used to reliably
predict protein-ligand structures.
Protein-ligand interactions, described by the induced-fit model
of molecular recognition, involve structural alterations in the
receptor binding site and the ligand. Thus, it is critical that the
model allows for flexibility in both the ligand and the receptor.
The compouter programs AUTODOCK, GOLD, GLIDE, FLEX
etc, which we have now integrated into our studies of protein-
ligand interactions, allow partial flexibility of the receptor and
full flexibility of the ligand . flexibility of the ligand and recep-
tor is computationally cumbersome to include in the docking
simulations.If the ligand and the receptor are completly flexible
during the simulation, even if we exclude everything else but
the receptor binding site, the computational cost of the docking
problem becomes so great. Proper ways to accomodate flexibility
in the docking simulations without increasing the computational
effort too much is one of the most important issues in the de-
velopment of new metodologies at the moment.Computer-aided
ligand-receptor docking has become an important research tool
in structural biology.
1.1.1 Autodock
AUTODOCK (current version 3.0 and 4.0) docks flexible small
moleculae ligand to rigid macromolecular recepor and with some
residue flexibility of receptor. In the docking simulations the
number of rorsional degrees of freedom in the ligand can be
varied, but some angles and bond distances are maintained rigid.
AUTODOCK uses Monte-Carlo simulated annealing and/or
Lamarckin genetic algorithm minimization scheme combined
with a rapid, atomic resolution, grid based method of energy
evaluation utilizing the Amber force field. In order to find low
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energy confermations of ligands in the receptor binding site.The
overall interaction energy between chemical species (i.e between
atoms of the ligand and the receptor) is estimated by consider-
ing both Lennard-Jones atom-atom potential and electrostatic
effects, summed for the individual interactions between atoms. A
distance-dependent dielectric constant or special solvation energy
grid can be used to account for the solvent effects.
Stoddard and Koshland were pioneering users of AUTODOCK
in a clever prediction of a structure of a peotein-protein com-
plex by docking seprate domains. apartm from many uses of
AUTODOCK in various ways of protein ligand interaction, it also
helped in invention of a drug which is in clinical trials for HIV.
McComman et al in 2007 used AUTODOCK in conjunction with
the Relaxed Complex Method. Merck Pharmaceutical company
used McCommon’s et al group protocol of AUTODOCK to de-
sign new drugs that target integrase, which lead in October 2007
to the first clinically approved HIV Integrase inhibitor:Isentress.
The docking of the ligands was explored with AUTODOCK
and the docking energy produced with the AUTODOCK force
field was corrected with the energy needed to solvate the ligands
1.1.2 Protocol
Autodock 4 was used for all docking calculations(Morris GM
et al journal of computational chemistry; 2009). The AutoDock-
Tools(ADT) package was employed to generate the docking files
and analyze the docking results. In the abscence of literature data
for the binding of different class of compounds, we performed
molecular docking taking carben alpha atom. of the respective
resistant mutant of the corresponding site as in case of HCV and
the resistant mutation isolated from our lab in case of BVDV, as
a grid center, for each compounds. The interaction pattern and
key residues of crystallized ligand (table1), which correspond to
the binding site A, B, C, and D were used for the identification of
proper orientation of our compounds into the different binding
sites. Two different grid boxes, one for each binding site, were
centered on the average mass center of the ligands. Thus, a grid
box of 91 X 91 X 86 points and a grid spacing of 0.375Å was set
in order to accommodate the NNIs that bind on to the different
sites of NS5B polymerase.
The second grid box (spacing,0.375Å) of 62 X 75 X 75 points
was implemented in such a way to accommodate the NNIs into
the more buried area of NS5B. The grid maps were generated
for each atom probe, describing its interactions with the com-
pounds. Autogrid 4, as implemented in the Autodock software
package, was used to generate grid maps. The Lamarckian ge-
netic algorithm (LGA)62 was employed to generate orientations
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or conformations of the ligands within the binding site. The
global optimization started with a population of 150 randomly
positioned individuals, a maximum of 2.5 X 108 energy evalua-
tions, and a maximum of 27,000000 generations, as mentioned
the protocol for blind docking. A total of 200 runs was performed,
while all the remaining run parameters were maintained at their
default settings. A cluster analysis was carried out using 2Å as
the root-mean-square deviation tolerance. Docking experiments
were also tried using a single grid box comprising the two bind-
ing sites. Although Autodock performed quite well in selectively
positioning the ligands in the right pockets, the results in term of
root-mean-square-deviation (rmsd) values were not fully satisfy-
ing. This is likely due to the fact that with only 100 runs such a
large region is not sufficiently explored. Nevertheless, a higher
number of conformation sampling, may not assured better results
in the absence of required no. of runs. So we went for 200 runs
although it was computationally demanding.
1.2 assessment of docking
1.2.1 Redocking
. Further refinement of docking was performed, aiming to check
out the more realistically binding mode conformations of com-
pounds with no experimental data. In order to check for the
reliability of the docking protocol, we performed docking studies
on NS5B polymerase complexes. The docking results were eval-
uated through a comparison of the predicted docked positions
of the ligand and the experimental ones. As a measure of dock-
ing reliability, the rmsd between the positions of heavy atoms
of the ligand in the calculated and experimental structures was
considered.
The choice of the best conformation was based on the assump-
tion that, although for high-throughput screening protocols, only
the first ranked conformations should be considered (that is, the
conformer characterized by the lowest estimated free energy of
binding)63. In other cases, the lowest energy conformer of the
most populated cluster should also be taken into account64. We
applied the second protocol for investigation of binding mode
of newly identified potent lead of different class of compounds.
While the best docked is the lowest energy docked conformations
of the first autodock generated cluster.the best cluster is the low-
est energy docked conformation of the most populated cluster
and best fitted cluster is the lowest energy docked confermation
of the cluster showing the lowest rmsd value.In the ideal case, i.e.,
the error free docking program, the three conformations would
have coincided.
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The fact that Autodock reproduces the correct conformations
(best fitted cluster) by 100 percent reflects the intrinsic lack of
accuracy (at least for NS5B) of the implemented scoring function
in selecting the right pose, and this is at the basis for the further
analysis using molecular dynamics.
Flexibility of the ligand and the receptor is
1.3 molecular dynamics
Molecular Dynamics (MD) simulation is a technique founded
upon the basic principles of classical mechanics that provide a
dynamical picture of the individual particles of the system at a
microscopic level. Using this technique successive configuration
of the molecular system (in the phase space of coordinates and
momenta) is generated by integrating Newton’s law of motion.
The result is a trajectory, which contains the microscopic time
evolution of the system in the phase space [? ? ]. From the trajec-
tory generated, one can compute the dynamical properties such
as absorption spectra, rate constants and transport properties.
Further, on combining MD with statistical mechanics as a mean
of sampling, one can compute equilibrium properties such as
average thermodynamics quantities, structure, and free energies
along the reaction path seen as a union of all possible states of
the system [? ? ]. For instance, the statistical ensemble average of





The assumption made here is called the ergodic hypothesis, i.e
given an infinite amount of time, ensemble average of observable
A, is equivalent to its time average. The main aspect in atomistic
MD simulations are:
• An algorithm that samples the phase space
• The choice of the interaction potential, V(r), between the
atoms of the system.
Several simulations approaches were developed in the last
decades that differs in the method to sample the phase space.
The most fundamental form used to describe equation of motion









) = 0 (1.2)
where L(q,q˙) is Lagrangian defined as the difference between
the kinetic and potential energies L=K-V, where qj are general-
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ized coordinates and q˙j are the associated time derivative. The





On substitution with the usual definition of kinetic and poten-
tial terms with cartesian coordinates ri, equation 1.2 becomes:




where V(r), the potential, is a function of the atoms positions
and Fi represents the total force on atom i. In this equation one
assumes that the nuclear motion of constituent particles obeys
the laws of classical mechanics. This is an excellent approxima-
tion if the distance in the energetic (translational, rotational and
vibrational) levels of the involved degrees of freedom is << kT ,
where k is the Boltzmann constant and T the temperature.
In the Hamiltonian form the equation of motion for the carte-








1.3.1 Integration of Newton equations of Motion
Under the influence of a potential, the motions of atoms are
strongly coupled to each other giving rise to many-body prob-
lems that cannot be solved analytically [? ]. Therefore, in MD
calculation an iterative numerical procedure is employed to ob-
tain an approximate solution for the equations of motion.
The two important properties of the equations of motion to be
noted are:
• They must be time reversibe (t=-t).
• Conservation of total Energy (Hamiltonian) of the system.
For the first point, as the Newton equations are time reversible
also the algorithm used is supposed to satisfy the same time
reversal symmetry. The algorithms that are not time reversible do
not normally preserve the phase space volume, i.e. they do not
satisfy the Liouville theorem. For the second point, conservation
of Hamiltonian is equivalent to conservation of total energy of
the system and provides an important link between MD and
statistical mechanics. The energy conservation condition H(p,r) =
E, defines a hypersurface in the phase space called the constant
energy, imposing a restriction on system to remain on this surface
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[? ]. A good way to check the accuracy of the algorithm is to
follow the temporal evolution of an observable A that should be
conserved (e.g. the total energy). In general a good algorithm
must be such that:
| A(tn) −A(t0) |
〈A(t)〉  1, for (tn − t0) ∆t (1.6)
there is no drift in the total energy.
The MD integration of the Newton’s equation which have a con-
tinuous form, are based on assumption that position, velocities
and other dynamical properties can be discretized using the
Taylor series expansion:






∆t3b(t) + .... (1.7)






∆t3c(t) + .... (1.8)
The choice of the integration method depends on the degree of
accuracy of problem at hand. One of the most useful form used
is the velocity verlet algorithm [? ], a variant of verlet algorithm
[? ]. The advantage is using velocity verlet method is that posi-
tions, velocities and acceleration are well synchronized that allow
to calculate the kinetic energy contribution to the total energy
at same time, from which potential energy is determined. The
equations are:








where ai,ri,vi are respectively the acceleration on the atom i,
the atom position and the atom velocity. The algorithm has an
accuracy of O (∆t3) for the variables and it is reversible in time.
Together with conservation of energy and time-reversibility
another important feature of an integrating algorithm is to permit
long time steps ∆t. It is expected that the numerical Newtonian
trajectory will diverge from the “true” Newtonian trajectory. How-
ever, it is important that the integrating algorithm maintains a
well defined energy tolerance ∆E throughout the simulation time.
The error (∆E) is known to decrease on decreasing the time step
∆t. The aim here is to find a balance between using the largest
possible time step and maintaining an acceptable ∆E all along
the simulation. A large time step would lead to faster exploration,
but energy would fluctuate widely with the possibility of the
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simulation being catastrophically unstable, on other hand too
short time step would lead to computation being needlessly slow.
The choice of an integration step is determined by the nature of
forces acting on the system. The golden rule is to choose time
step (∆t ∼ 10−15s) such that the fastest motion of the system
can be integrated accurately. This requirement is a severe restric-
tion, particularly as high frequency motions are relatively of less
interest and have minimal effect on the overall behavior of the
system. One suggested approach is to freeze out such vibrations
by constraining the appropriate bonds to their equilibrium values.
Details of this approach is discussed in subsection 1.3.4, or to
use multiple time step approach which is discussed in subsection
1.3.2.
1.3.2 Multiple Time Step Integrator
One of the approaches to accelerate the integration of equations
of motion, is to use “multi-time” step algorithm such as reverse
reference system propagation algorithm (r-RESPA)[? ]. In the
algorithm (r-RESPA), the molecular system is classified into num-
ber of groups according to how rapidly the forces varies over
time. The starting point is the Liouville operator formulation,
which can cast the equations for the Hamiltonian system (see
equation1.5) in a general form:
x˙ = iLx (1.11)
where x is the phase vector and iL is the Liouville operator.
Consider a molecular system containing N atoms (or 3N degrees
of freedom) with x = {ri,pi} representing a point in the phase
space. The Liouville operator in cartesian coordinates is defined
as:















On subsituting equation 1.5 into equation 1.12, we get:












where Fi is the force on ith degree of freedom, and {...,...} is the
poisson bracket. The classical time propagator U(t) is unitary and
defined as eiLT , and the evolution of system Eq. 1.11 is expressed
as:
x(t) = eiLtx(0) (1.14)
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The action of operator U(t) on x(0) cannot be determined ana-
lytically, however the operator can be decomposed using Trotter
theorem, such that the action of U(t) on x(0)for each part can be


















where ∆t=t/P. For finite P, the numerical iteration procedure
is accurate to the second order in the time step at long times.
From equation 1.15, for the three exponential terms, we define












2 ) +O(t∆t2) (1.16)
Since the three exponential terms in G ∆t are separately unitary,
G (∆t) is also unitary i.e G−1(t) = G†(t) = G(-t). Lets us now














The operator U1(∆t2 ) becomes a translation operator on the
positions: ri → ri + ∆t( pimi ), and operator U2(∆t) becomes a
translational operator of momenta: pi → pi + (∆t2 )Fi(r). On com-
bining these two facts to action of operators in equation 1.16 on
complete set of positions and momenta, yields the approximate
evolution:




vi(∆t) = vi(0) +
∆t
2mi
[Fi(0) + Fi(∆t)] (1.18)
which is the famous velocity verlet [? ] integrator derived
using the operator formulation. The power of the operator based
approach is its symplectic property which ensures no drift in
the total energy, resistance to increase in time steps and allows
generating stable long trajectories.
60
r-RESPA algorithms have been successfully employed to in-
corporate motions on more than two time scales. Let us con-
sider a system with three characteristics time scales, a refer-









i . We define their Liouville operators as iL
ref,
iL(del) and iL(Del) and the corresponding timescales δt, ∆t and




































Thus, the correction due to slowest time scale is applied every
m×n timesteps, and the intermediate time scale correction is
applied every n steps. Such numerical procedure lead to consid-
erable saving in the CPU time to perform a MD simulation.
1.3.3 The interaction potential
Figure 1: force field
The potential function V(r) from which the forces used in MD
are derived depends on the atomic coordinates ri.
V(r) used in this thesis has the following expression:
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The first two terms (two and three body interactions respec-
tively) represent the bonds and angles potentials, that are ap-
proximated by harmonic functions. The third and fourth term
describe four body interactions. Improper dihedral terms are
typically described by an harmonic function. Instead proper di-
hedrals are described by periodic functions (i.e. cosine functions)
of a given periodicity n. The last two terms are a Lennard-Jones
(LJ) potential and a coulomb potential between pair (ij) of atoms.
The LJ terms reproduce the Van der Walls interactions, while the
coulomb potential terms reproduce the electrostatic properties
of a protein. These interaction are modelled using the two-body
approximation which doesnot explicitly account for the polar-
ization effects, but on a average. The parameters used in this
kind of potentials are typically obtained from quantum chemical
calculations and experimental data (e.g. crystallographic data,
spectroscopic data, etc). Among the popular sets of parameters
(force fields) for MD simulations of proteins we can cite for ex-
ample AMBER, GROMOS, CHARMM and OPLS. They all use
the potential function expression given above for all the atoms of
the simulated system except for the GROMOS(and CHARMM19
force field) force field in which a united atom description is used
for non-polar hydrogens.
In MD simulations the description of the solvent (water for
most of the biologically interesting systems) can be explicit or
implicit. In the first case solvent molecules with a full atomistic
force field description are added in the simulation box at the ex-
perimental density. In the implicit solvent description the solvent
is treated as a dielectric medium in which the system is embed-
ded. This is clearly a more approximated description but it is
also computationally much more efficient since in many practical
cases the solvent constitutes the majority of the atoms. In this
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thesis we used for all the MD simulations the AMBER-95 and
AMBER03 force field with an explicit description of the solvent
given by the TIP3P[? ] water model.
1.3.4 Constraints for Hydrogen
Constraints are used in MD to fix bonds to their equilibrium value.
This allows increasing the simulation time step ∆t. Constraining
the bond lenght does not alter significantly the statistics as these
are quantum degrees of freedom being mostly in their ground
state at the normal simulation temperature. Using the bonds
constraints it is possible to use ∆t ∼ 2fs [? ] (2-4 times larger than
the one that can be used without constraints). A common method
to introduce constraints is the algorithm SHAKE [? ], in which
after each time step the atoms positions iteratively are modified
in order to satisfy the constraint.
SHAKE may have convergence problems when applied to large
planar groups and its implementation could hinder the efficiency
of computing. To improve these aspects the LINCS algorithm was
recently introduced. For water molecules it is also possible to use
an analytic solution of SHAKE called SETTLE.
1.3.5 Boundary conditions
To simulate a finite size system, boundary conditions are needed
to avoid artifacts near the border of the simulation box. Typically
periodic boundary conditions (PBC) are used. In this scheme
short range non bonded interactions are calculated using the
minimal image convention (only the nearest replica is considered).
Typically a cut-off radius (Rc) is used for LJ interactions of the
order of 10 Å. To avoid interactions between a particle and its
periodic image each box side must be larger than 2Rc.
The coulomb energy is instead treated considering the full pe-
riodicity of the system. For a periodic lattice made by N particles














where n indicates the periodic images, i,j the particles and the
symbol ? indicates that the summation does not contain the term
with i = j if n = 0.
The periodicity of the system speeds up the evaluation of the
coulombic term. Although convenient, effective, and simple to
apply, certain subtle problems arise for long range forces (electro-
statics), whose spatial range may extend beyond the boundaries
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of the container into surrounding images, present a challenge.
Long range forces can only be correctly calculated by summing
over all the periodic replicas of the original system. However,
the associated computational effort is considerable. Fortunately,
methods have been developed to treat this problem. Specifically,
the Ewald summation technique, developed originally to treat
Coulomb interactions and later extended to treat general interac-
tions of the form
1
rn
for n6 3 has proved enormously successful.
The basic idea behind the technique is to divide the relevant part
of the potential into a short range and a long range contribution.











where erf(x) and erfc(x) are the error function and complemen-
tary error function, respectively (erf(x) + erfc(x)= 1). The variable,
R, is a convergence parameter, which can be optimized for each
system studied. The short range term, erfc(αr)/r, is treated as
an ordinary short range interaction, i.e., using a spherical cutoff
to truncate the interaction at large spatial distances where the
potential is small. The long range term, erf(αr)/r, is Fourier trans-
formed into reciprocal space, where it takes the short-ranged
form, exp(-g2/4α2), and can be evaluated accurately by sum-
ming over only a small number of reciprocal space vectors of
the simulation cell. Such reciprocal space sums can be evaluated
with high a degree of efficiency (N log N) using particle-mesh
methods(PME)[? ]. An extension of PME is the smooth PME.
With respect to PME, this method uses a fixed cuttoff in the
direct sum and uses the B-spline interpolation of the reciprocal
space structures onto a rectangular grid, permitting the use of
fast Fourier transforms to efficiently calculate the reciprocal sum.
In this thesis we use SPME method to evaluate the electrostatic
energies[? ].
1.3.6 Statistical Ensembles
Molecular dynamics can be performed in different statistical en-
sembles. The traditionally used ensemble to perform MD is the
micro-canonical ensemble (NVE), where the number of particles
(N), the volume (V), and the total-energy (E) of the system are
fixed to a constant value.
The simple extension of NVE ensemble is the canonical one
(NVT), where the number of particles, the volume and the tem-
perature are fixed to a constant value. The temperature T, in
contrast to the number of particles N and volume V, is an inten-
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sive parameter. The temperature T is related to the time average















where, Ekin is the kinetic energy, kB is the Boltzmann constant.
The simplest way to control the temperature, is to rescale the




, where Tcurr is
the current temperature calculated from the kinetic energy and
Treq is the desired temperature (for instance 300 K). However,
an alternative way to maintain is to couple the system to an
external heat bath that is fixed at the desired temperature. The
bath acts as a source of thermal energy, supplying or removing
heat from the system as appropriate. This thermostat is named
as the “Berendsen” thermostat. It is extremely efficient for re-
laxing a system to the target temperature, but once the system
has reached equilibrium, it might be more important to probe a
correct canonical ensemble.
Extended system methods, was originally introduced for perform-
ing constant MD simulation by Nosè in 1984, and subsequently
developed by Hoover in 1985. The idea of the method was to
reduce the effect of an external system, acting as a heat reservoir,
to an additional degree of freedom s. This reservoir has a po-
tential energy (f+1)kBTln s, where f is the number of degrees of
freedom in the physical system and T is the desired temperature.








Q is considered as the fictitious mass of the extra degree of free-
dom. The magnitude of Q determines the coupling between the
reservoir and the real system and so influences the temperature
fluctuation. If Q is large then the energy flow is slow; in the
limit of infinite Q, conventional molecular dynamics is regained.
However, if Q is small then the energy oscillates, resulting in
equilibrium problems. It has been suggested that Q should be
proportional to fkBT.
Another ensemble we discuss here it the NPT ensemble, an ex-
tension of NVT ensemble, where together with temperature the
pressure of the system is maintained to a constant vaue. As most
experimental measurements are usually made under conditions,
which include a fixed pressure P, temperature T, and number
of atoms N (constant-NPT ensemble), and so simulations in the
isothermal-isobaric ensemble are the most directly relevant to
experimental data. A simulation in NPT ensemble maintains the
constant pressure by changing the volume of the simulation cell.
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An alternative to maintain constant pressure is to couple the
system to a “pressure“ bath, analogous to the temperature bath.






(Pbath − P(t)) (1.25)
where τp is the coupling constant, Pbath is the pressure of the
’bath’, and P(t) is the actual pressure at time t. The volume of
the simulation box is scaled by a factor λ, which is equivalent to
scaling the atomic coordinates by a factor λ1/3. Thus:




and the new position are given by:
ri
new = λ1/3ri (1.27)
In the extended pressure-coupling systems, an extra degree
of freedom, corresponding to the volume of the box, is added
to the system. The kinetic energy associated with this degree
of freedom (which can be considered to be equivalent to piston







), where Q is the ’mass’ of
the piston. The piston also has a potential energy PV, where P
is the desired pressure and V is the volume of the system. The
volume varies in the simulation with the average volume being
determined by the balance between the internal pressure of the
system and the desired external pressure. In this thesis, we have
performed MD simulation in both NVT and NPT ensembles.
1.3.7 Solvation effect
In most cases, we are interested in the properties of molecules
in solution, usually in aqueous solution. therefore, it is essen-
tial to calculate not only the interaction between the atoms of
biomolecules, but also the solvent effect on the interaction. there
are two different approches to include the solvent effects in molec-
ular dynamics. One is explicit solvent model, the other one is
the continuum solvent model, also known as the implicit solvent
model.
In explicit solvent models we need to calculate the interaction
between the particles and every solvent molecule individully,
therefore it is a very “computationally expensive ” job, and the
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cost increase with the number of interaction sites in the water
model. Algorithms such as Particle Mesh Ewald (PME) method,
particle-particle/particle-mesh(P3M) method are developed to
accelrate the simulations.
Even with advanced algorithms, one obvious drawback of the
explicit solvent model is the large system size due to numerous
solvent molecules. An alternative approch is using the contin-
uum solvent models, such as the Generalized Born(GB) model.
This model represents the solvent implicity as a continuum with
dielectric properties of water, and also includes the charge screen-
ing effects of salt. this lowers the calculation expense in two
aspects: first, it removes the calculation of the interactions and
motions involving solvent molecules;second, the absence of sol-
vent friction accelerates the dynamics of the solute. However, the
computing cost of GB model scales up with the size of the system.
for large systems, the computing cost may be greater than using
explicit solvent model.
Both explicit solvent and implicit solvent models have cer-
tain strengths and weakness. Calculations using explicit solvent
generally yield more accurate results. In some cases, such as
simulations involving water bridges, explicit water molecules are
essential for the calculation. However, systems using explicit sol-
vent have many more atoms (in most case mostly water molecules
), demanding additional computing resources. Due to the fraction
force from water molecules, the dynamics of the solute is also
slower in the explicit solvent. this may be useful for understand-
ing the real time scale of a biological event. However, for some
studies where rate is not a factor, but the results of the motion
are important, the implicit solvent model will be more efficient.
Another important advantage of implict solvent model is that it
calculates solvent free energy, instead of energy. In the explicit sol-
vent model, water atoms are considered to be part of the system,
and solvent-solute interactions are included in the non-bonded
calculations. There is no independent solvation term. In implicit
solvent the simulated system only includes solute. the molec-
ular mechanic interactions are calculated first in vacuum. then
an additional term, the solvation free energy is calculated and
included in the energy of the system. the implicit solvent mimics
the average effects of the water molecules, therefore it genrates
solvation free energies. it is essentail for methods such as Molec-
ular Mechanics-Poisson Boltzmann (Generalized Born) Surface
Aea (MM-PB(GB)SA) approch, which needs an explicit solvation
free energy term in calculation. just a note, MM-PB(GB)SA is a
post-processing analysis, which means it is still recommended
to genrate the structures using explicit solvent first, then using
implicit solvent model to analyze the solvation free energy on
existing structures.
67
1.4 long time scale simulations
Molecular Dynamics (MD) simulations allow investigating pro-
cesses occurring on timescales of ∼100ns. However, most interest-
ing and relevant biological process happen on time scales that
are orders of magnitude larger, and are therefore termed as rare
events. For example, protein folding (µs-few seconds), protein-
protein interactions, transport of molecules across membrane
channels (order ∼ µs) and many others. Over the years, we have
observed an astounding increase in computer power (Blue gene,
DESRES), which promise to increase utility of MD simulations
to investigate more and more complex systems on µs timescale.
However, these supercomputing machines are not available to all
the research groups. Therefore another approach to overcome the
timescale problem is to renounce the all atom approach and to
use coarse grained models. This would retain the essential char-
acteristics, however you require a detailed knowledge of system,
that is often not available.
For systems, where its important to maintain the atomistic de-
scription, one can exploit methodology aimed at accelerating
rare events to timescales reachable in MD simulations. Notable
success has been achieved is using the accelerating methodol-
ogy in diverse fields of interest. From their scope and range of
applicability, they are classified in four categories [? ]:
1. Methods aimed at improving sampling, in a subspace of few
predefined collective variables (CVs), that allow reconstruct-
ing the probability distributions as a function of chosen
CVs. Examples of these methods include thermodynamic
integration [? ? ], free energy perturbation [? ], umbrella
sampling [? ], conformational flooding [? ], weighted his-
togram [? ? ? ], steered MD [? ], Jarzynski’s identity based
methods [? ] and adaptive force bias [? ]. The power of these
methods in highly dependent on judicious choice of CVs,
and computational performance degrades as a function of
the number of variables.
2. Methods aimed at exploring the transition mechanism. Ex-
amples in these catogeries are transition path sampling[?
? ], finite temperature string method [? ? ], transition in-
terface sampling [? ] and forward flux methods [? ]. These
methods do not require in most cases, an explicit definition
of a reaction co-ordinate, but require a priori knowledge of
initial and final states of process under investigation.
3. Methods for exploring the potential energy surfaces and
localizing the saddle points that corresponds to a transition
state. Examples in these catogeries are dimer method [? ],
hyperdynamics [? ], multiple time scale accelerated MD [? ]
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and event based relaxation [? ]. The power of these methods
is limited to low dimensionality, and reliability degrades
with the complexity of system.
4. Methods in which the phase space is explored simulta-
neously at different values of temperatures, are parallel
tempering [? ] and replica exchange [? ], or as a function of
the potential energy, such as multicanonical MD [? ] and
Wang-Landau [? ].
1.4.1 Metadynamics
Metadynamics method encompasses several features of tech-
niques mentioned earlier and provides a unified frame work
for computing free energies and accelerating rare events. It is
a powerful algorithm, based on dimensional reduction that is
used for accelerating rare events in system described by com-
plex Hamiltonians, at a classical or quantum level [? ]. Before to
use the algorithm, the requirements are to identify a set of CVs,
which are assumed to describe well the process of our interest.
The power of the algothim lies in treating the CVs simultaneously
and in its flexibility: the method can be proficientely used both
for reconstructing free energy and for accelerating rare events.
1.4.2 The algorithm
Consider a system described by a set of co-ordinates x and a
potential V(x) evolving under the action of molecular dynamics,




). Since our interest is to describe the system using a set of
CVs, Sα(x), α=1,d where d is a small number assuming they
provide a good coarse-grained description [? ]. The equilibrium

















where s denotes the d dimensional vector (s1,....,sd), with the free
energy given by:












in equation 1.29, capital S is used for representing the function of
the coordinates S(x), while lower case s is used for denoting the
value of the CVs.
Consider now a trajectory x(t) of the system at temperature T.
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On computing the trajectory for a very long time, probability
P(s) can be obtained by taking the histogram of CV s along
this trajectory. At time t, P(s) ∼ 1t
t∫
0
dt ′δ (S(x(t’) - s). If the system
displays metastability, the motion of s will be bound in some local
minimum of F(s) (i.e., in local maximum of P(s)), and will escape
from this minimum with a very low probability on the timescale
determined by the potential V(x) alone. In Metadynamics, the
metastability is eliminated by modifying the underlying potential
V(x), by adding a history dependent term consisting of Gaussians
centered along the trajectory in s space during the evolution of
the system [? ? ]. Each time a new gaussian is added at time τG,
the biasing potential at time t is given as:





(S(x) − s(t ′))2
2δs2
) (1.30)
In equation 1.30 capital S is used for denoting the function of
the co-ordinates S(x), while lower case s is used for denoting the
value of the CVs, s(t)=S(x(t)) is the value taken by the CV at time
t, ω is gaussian width, δs is the gaussian width and frequency τG
at which gaussians are added. The basic assumption of metady-
namics is that VG(s,t) defined in equation 1.30 after a sufficiently
long time provides an estimate of the underlying free energy:
lim
t→∞VG(s, t) ∼ −F(s). (1.31)
Here, in equation 1.31, a equilibrium quantity free energy (F(s))
is estimated by a non-equilibrium dynamics. Equation(1.31) can
be qualitatively understood as slow ’deposition’ (i.e. ω→ 0), and
in this limit VG(s,t) varies very slowly, with the probability to




(s,t))]. If the function F(s)+VG(s,t) has some local minimum, s will
be preferentially localized in the of this minimum and Gaussians
will be deposited, till the minimum is filled. If we consider the
situation where F(s) ∼ −VG(s,t) in a region Ω(s). In this case
the probability distribution would be flat and the locations of
the gaussians will not be affected by the bias. Hence, if ω →
0, only corrugations in the free energy that are not flattened by
the dynamics will be the order of the size of the newly added
gaussians.
In most cases, it is not sufficient to describe the process of interest
using a single CV, therefore in cases where we use more than one
CV at the same time, the metadynamics potential is given by















and it is necessary to choose metavariable δsα for each CV. The
time required to escape from a local minimum is determined by
number of Gaussians needed to fill the basin. This number is
proportional to (δsα)d where d is the number of CV chosen to
describe the system. The efficiency of the method scales exponen-
tially with number of CV. The added gaussians can reproduce
features of the FES on a scale larger than δs. The quality and
accuracy of the free energy construction is highly influenced by
the parameters of metadynamics. The parameters need to be
chosen wisely, striking a balance between accuracy and efficiency.
1.4.3 How to Choose CVs
Reliability of Metadynamics is highly dependent on the choice
of CVs, and this in turn depends on the process of investigation.
Therefore if not essential it is important to have good knowledge
of the process under investigation, which aids in chosing the
right CVs. Important features that CVs must satisfy are:
1. They should be slow variables able to describe well the
process of interest.
2. They should be able to distinguish between the initial, in-
termediate and final states.
Practical Example of choosing CVs
For example, lets consider the diffusion of antibiotics through
OmpF channel. The OmpF channel has an axis of symmetry
along Z-axis, with a hourglass shape. Here we want to follow the
exit of antibiotic from the channel. In this case, one appropriate
CV would be distance: defined as difference between the center
of mass (com) of the antibiotic (a1) and the center of mass of











We make a assumption in equation 1.33, com of OmpF (p1) is
constant respect to com of the antibiotic(a1). Therefore using
this CV sdist we caputure the location of antibiotic in the OmpF
channel.
1.4.4 Estimation of Error
Error estimation in Free energy calculations is very much depen-
dent on the meta variables (ω, δs, τG). In [? ] it has been shown
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that the error on reconstruction profile is determined by the ratio
of (ω/τG) and not by ω and τG alone. For instance, adding Gaus-
sian of height ω=1.0 Kcal mol−1 every τG = 4ps, is equivalent to
adding Gaussian of height ω=0.5 Kcal mol−1 every τG = 2 ps,
with a requirement that τG remains much shorter than the time
required to fill the free energy basin. The error  in metadynamics
is a measure of expected deviation of VG(s,t) from -F(s):
ε2 (s) =
〈











Remarkably, the error does not depend on F (s). An alternative
expression for for the error, dependent on parameters: w/τG, T ,







where Cd is a constant that depends only on the dimensionality.
The two expressions for the error share the same functional
dependence on w/τG, T , D and S. The ratio between the two
expressions is approximately a constant as a function of δs only
for d = 1 and d = 2, while significant deviations are observed in
higher dimensions.
The dependence of the error on the simulation parameters
becomes more transparent if ε is expressed as an explicit function
of the total simulation time. Consider in fact a free energy profile
F (s) that has to be filled with Gaussians up to a given level Fmax
, for example the free energy of the lowest saddle point in F (s).
The total computational time needed to fill this profile can be
estimated as the ratio between the volume that has to be filled
and the volume of one Gaussian times τG :


















D is the average time required for the CVs to diffuse


















is a function of δsS and of the dimensionality alone. Eq. 1.38 states
that the error of a metadynamics reconstruction is inversely pro-
portional to the square root of the total simulation time, measured
in units of the diffusion time. The error will be large for slowly dif-
fusing systems, in which the walker takes a long time to explore
the CVs space.
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1.5 advanced md simulation methods
1.5.1 MM-PBSA
one of the major goals of the computational chemistry is to de-
velop methods to accurately predict the binding eergy of a ligand
to a protein. This is of central interest in medicinal chemistry,
because the action of most drugs (inhibition, activation etc.) is
caused by the binding of the drug to its target receptor. However,
many biochemical problems can be treated in a similar way For
example, the reactivity of an enzyme can be estimated by com-
paring the free energy of the reactant and tranisition states of
the active site in protein. Therefore, many methods have been
developed with this aim [? ? ]. MM-PB(GB)SA method is another
free energy calculation method(107). Unlike other free energy
calculation methods like free energy perturbation (FEP) or Ther-
modynamic Integration(TI) method, this is the post-processing
method, which means it calculates the free energy based on
existing structure snapshots. MM-PBSA restrict the molecular
simulations to the states before and after the binding process.It is
an attractive approch because it does not contain any parameters
that var for different ligands-receptor systems and it involves a set
of physically well defined term: The binding affinity is estimated
from the free energies of the receptor, the ligand and the complex.
In MM-PB(GB)SA calculation, the free energy of the system is
divided into three parts: molecular mechanics energy(MM), and
non polar solvation free energy (SA). The MM energy usually
consists of electrostatic energy and vander walls energy of the
system in vacuum. In some applications the bond energies, an-
gle energies, and dihedral angle energies are also included in
MM energy. the entropy of the system can be included by using
normaol mode analysis or other methods.
In this method to estimate the free eergy of the complex sys-
tem, one carries out a molecular dynamics simulation, typically
in a periodic box with water and counter ions, and correct rep-
resentation of long-range electrostatic effects, saving a set of
representative structures. then one post process these structures,
remove any solvent and counter ions molecules, and calculates
the free energy, G, accordign to the following equation:
4Gbind = 4EMM +4GPBSA − TSMM (1.39)
or
4Gbind = Gcomplex − (Greceptor +Gligand) (1.40)
where4Gbind is the calculated average free energy, and4EMM
is the average molecular mechanical energy,Gcomplex,Greceptor,
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and Gligand are the free energies of the complex, the protein,
and the ligand, respectively.
For each system, the free energy can be estimated in terms of
molecular mechanic potential energy EMM, the solvation free
energy Gsolv, and the entropic contribution (TS) as fallows:
Gbind = EMM − TS+Gsolv (1.41)
EMM = Einternal + Eelec + EvdW (1.42)
Einternal = 4Ebond +4Eangle +4Etors (1.43)
Gsolv = Gelec,solv +Gnonpolar,solv (1.44)
where these correspond to the bond, angle, torsion, van der
waals, and electrostatic terms in molecular mechanical force field,
evaluated with no non-bonded cutoff. All the terms in Eq. 1.42 are
averages of energies obtained fron a number of snapshots taken
from the MD simulations [? ]. In order to reduce the the time
consumption and to obtain the stable energies, the same geometry
is normally used for all three reactants (complex, receptor,ligand),
i.e only the complex is explictily simulated by MD.There by,
Einternal cancels in the clculation of 4Gbind. The MM-PBSA
methos has been successfully applied to many systems [? ? ],
[? ? ? ]. Gpbsa is the solvation free energy calculated with the
numerical solution of the Poisson-Boltzmann equation and an
estimated of the non-polar free energy with the simple surface
area term. The nonpolar solvation contribution is estimated as
GSnonpolar,solv = γA+ b (1.45)
Where A is solvent-accessible surface area and the solvent param-
eters, γ and b, are 0.00542 kcal/mol Å2 and 0.92 kcal/mol, respec-
tively.the probe radius of the solvent was set to 1.4 . the atomic
radii of of the solute were taken from PARSE parameter set [? ? ].
−TSMM is the solue entropy, which can be estimated by quasi
harmonic analysis of the trajectory or by using normal-mode
analysis (108). the solvant entropy is included tin the solvation
free energy term. The free energy due to ionic strength effects
can be added with a continuum approch.
The ability to accuratly calculate 4G, the average free energy,
we can calculate 4G for a given macromolecular system in vari-
ous different confermations or structures, adds a very important
methodology to our computational arsenal. This has been pos-
sible before with free energy perturbation but only for small
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systems and very limited conformational or topological changes.
By using continuum model, it is implicity integrating out all
the solvent coordinates and simplifying the problem. Also, by
calculating the absolute free energy directly with eq 1.2 between
the two “end points” instead of calculating the relative free en-
ergy along a mapping coordinate, we are avoiding computations
of eq 1.1 will have intrinsically much larger errors than free en-
ergy perturbation/thermodynamic integration calculations. What
is surprising is that, despite these larger uncertainties, we can
often calculate 4G in respectable agreement define with experi-
ment.(107)
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aqueous   solution.  Then,   we   selected   representative   equilibrium   conformations   by   performing   a   cluster 
analysis,  and ran docking calculations of 277G on representative of the 5 most populated clusters of each  



























































































well  plates  and  incubated overnight at  37°C in a humidified  CO2  (5%) atmosphere.  Cell  monolayers  were 
infected, in the first passage, with a m.o.i of 0.01 and after two hours treated with a drug concentration equal to  
the EC50. Multiwell were daily observed until they exhibited a 75­80% of cytopathic effect. The procedure was 














primers.   The   comparative   analysis   of   the   chromatograms   allowed   us   to   deduce   the  mutation   pattern 
responsible for resistance to 227G (BVDV227G).
Primers and parameters used in the RT­PCR reactions. 
The   primers   used   in   the   reverse   transcription   reaction   were   RT3     5’­ 
CCCCACAAACCATATCTGATTATTTCTTCTTTA­3’ and RT5b 5’­GTAGATAATCTTGACTACTGTTTAGCTCTTGAG­
3’, both of 33nt, that respectively bind 360bp downstream the NS3 gene and 90bp downstream the NS5b gene.  
cDNAs   were   amplified   by   PCR   using   Platinum  Pfx  DNA   Polymerase  (INVITROGEN),   following   the 
manufacturer’s protocol. The region containing NS3 gene and was amplified by PCR reactions carried out with 




the   primers   C   (5’­ATTATAAAGGAGGTAGGCTCAAGGA­3’)   and  D   (5’­CCATCTGCTGTTATAACTGGTACTT­3’) 




                                                                           5
       Computational
Structures of Receptors
The published X­ray crystal  structures of  BVDV RdRp [49]  (PDB code 1S48;  resolution 3.0 Å)  was used as 











































together more than 75% of  all  conformations,  while 95% of  conformations are contained in the  first   four  
clusters.   Interesting,   a   really   dominant   cluster   has   been   found   only   in   the   presence   of  mutation.  The 
corresponding representative structures of Clus1 and Clus2 for each system are shown in Figure 2A1.









was   chosen   as   the   grid   center   for   all   docking   runs.  The   choice   is   guided   by  mutagenesis   experiments 
performed on BVDV, showing that mutation Ile261Met produces resistance to 227G (see Ref.  Coupled paper; 
Ile261Met  mutation   is   resistent  mutant   for  phenyl­benzimidazole[80]   and  arylazoenamine   [81].     For   the 
complexes grid maps were made of 30x40x40 points in x, y, z directions, distant 0.375 Å from each other. 















Å   and   donor­hydrogen   acceptor   angle   larger   than   150°.  HpHs   are   counted  when   non­polar   atoms   are 
separated by at most 3 Å. The durable HB is defined as the one with a lifetime equal to or higher than 20% of 
MD simulation time, and transient HB are the one with a lifetime shorter than 20% of simulation time [87].  For 




residues  in  flexible  loops  in  this  region, and the area of  the entrance region along the whole equilibrium 








the  calculation  we calculate   the  area  of   the   triangle  whose  vertex  are  defined  by   the  centers  of  mass  of 
minimum­distance   atoms   in   every   loop.  We   are   aware   that   the   area   calculated   in   this  manner   is   an 
approximation and its absolute value has no quantitative meaning. Nevertheless, a comparison of the mouth 
areas   provides   a   qualitative   indication   of   the   space   available   to   the   template   RNA   strand   to   enter   the 
polymerization site. 

















subjected   to   RNA   extraction,   RT­PCR   and   sequencing   of   region   of   the   BVDV   genome   encoding   for 
nonstructural proteins NS3­NS5B, the principle enzymes involved in replicative complex:  NS5B, the RNA­
dependent  RNA  polymerase   (RdRp);  NS3,   a  multifunctional  protein  with  helicase,  NTPase   and  protease 
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Computational





















found  again   in   the  N­terminal  domain.   Indeed,   the  presence  of   the  point  mutation   I261M affects  quite  
significantly the structure (and the dynamics, vide infra) of the protein: the RMSD has a value of 4.3 A between 
the closest­to­average structures  along the dynamics,  and even  larger  values are  found in the N­terminal 
domain and between the conformations assumed by the linker (Table 3). This can be seen more clearly in  
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Cluster APO APOm COM COMm
Clus1 902 (45.1%) 1473 (73.6%) 906 (45.3%) 1307 (65.3%)
Clus2 795 (39.7%) 445 (22.2%) 669 (33.4%) 386 (19.3%)
Clus3 144 (7.2%) 51 (2.5%) 325 (16.6%) 192 (9.6%)
Clus4 68 (3.4%) 24 (1.2%) 79 (3.9%) 113 (5.6%)
Clus5 63 (3.1%) 8 (0.4%) 20 (1.0%) 3 (0.1%)
Clus6 18 (0.9%) ­ 1 (0.0%) ­
Clus7 11 (0.5%) ­ 1 (0.0%) ­
Table 1. Clustering of protein trajectories. Clustering of protein structures performed for each system over the last 20 ns of MD simulation  
(2000  frames).  In  each  system two main clusters  were   found grouping  together  more   than  75% of  all  conformations,  while  95% of  
conformations are contained in the first  four clusters.  Interesting,  a  really dominant  cluster  has been found only in the presence of  
mutation. The corresponding representative structures of Clus1 and Clus2 for each system are shown in Figure A1 
                                  
Clus1 Clus2 Clus3 Clus4
APO APOm APO APOm APO APOm APO APOm
Protein 2.4 4.4 2.6 4.0 2.9 4.9 2.6 3.7
Binding site 2.3 3.4 2.6 2.5 3.0 4.5 3.4 3.5
N­terminal 3.4 5.4 3.2 5.5 3.4 5.9 3.6 4.8
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Average Structure
Protein Binding­site N­terminal Linker
4.3 5.4 11.5 8.4
Cluster (protein)
Clus1 Clus2 Clus3 Clus4 




the  first   four clusters extracted from APO and APOm dynamics (see Table 1).   In Table 4 and Figure 4 are 
reported the results and the conformations of the 16 highest­score poses. The criterion we used to select these 









































Clus1 ­7.3 60 30 ­7.9 88 44
Clus2 ­7.9 174 87 ­8.2 5 2.5
Clus3 ­7.3 97 48 0 0 0





Clus1 ­8.2 76 38 ­7.9 97 49
Clus2 ­8.8 122 61 ­8.7 110 55
Clus3 ­7.2 122 61 ­7.0 36 18









           Clus3  Clus4


















complexes 2(Figure 1).   In particular,   the  linker   loop    is   in closer  contact  with 227G only  in complexes 2.  
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While   this  picture   is  helpful   in   conveying   the  dynamics  of   the  overall   structures,  we  were   interested   in  
understanding which parts  of   the protein  were more  flexible  and affected by the I261M mutation by the  
interaction with 227G. Henceforth, we monitored the RMSD of the backbone atoms in function of the residue 
number of  protein  and  ligand (Figure 6B).   It   is  obvious  from the plot   that   the systems undergo different  
conformational changes in the four simulations. 
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The maximum deviation is observed always at the N­terminal domain (residue 92 to 142). The N­terminus 












macro,   2005;   JBC)  when  compared  with   the   x­ray,  while   rest   of   the   area   including   catalytic   site   remain 
conserved.  In figure2 the box2 correspond to linker or the L4 loop. The L4 loop, in the COM exhibited major 
difference with respect to other three system, where in formation of newly beta sheet was observed, which  
lacked   in  x­ray,  APO and APOm system respectively,  while   it   is  comparatively  short   in  COMm, originally 
formed with residue Glu123 to Asn132.   In  fact,   in APO,  APOm, and COMm system this  beta  sheet  is  not 
consistent  during   the   time  evolution  of  MD simulation  but   it   is   very  much  prominent   in  case  of  COM. 


















COM and  COMm systems  are   reported   in  Figure   5.  As  described   in  material   and  methods   section,   the 
structural  alignments  have  been  performed onto   the  most   rigid  palm sub­domain.  To  take   into  account  
completely stabilized systems all the analysis has been carried out in the last 20ns of the simulations. It can be  
clearly seen that RMSD of COM and COMm were found to stabilize after 4ns at average of 2.5 Ǻ,  showing 




Figure6   is   helpful   in   conveying   the   dynamics   of   the   overall   structures;   however  we  were   interested   in 

















the loop L4, wherein the APOm has a maximum RMSD of 16  and APO has 11  . By visual inspection of theǺ Ǻ  
trajectory it was found that there was a remarkable deviation of the loop L4 from the putative binding cavity  
with respect to the crystal structure as compared to the APO system. Similarly, in case of the COM and the 
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However, we were also interested in seeing which part of the protein were more flexible and affected by the 
resistant  mutation,   so  we  monitored   the   root  mean  square   fluctuations  of   the  C  atoms   (i.e,   somewhatα  
analogous   to   crystallographic   B­factors)   for   each   residue   during  MD   simulations.   figure7   compares   the 
calculated B­factors with the experimental ones from the x­ray structure. our data indicate that the larger 
fluctuations are concentrated in two regions corresponding to residues 123 to 133 called linker and 436 to 446 
called   loop3  of   the   binding   site,  which   are   flexible   loops   on   the   surface   of   the  protein   as   reported   in  
uncomplexed   core domain structures. The second loop 436 to 446, exhibits almost the same behavior in all  
three simulations except APO. The reduced fluctuation in case of APOm is due to the interaction with L4 loop, 
which deviate from it   initial  position and comes closer  to L3 loop. In case of COMP the loop L3 has  less  
flexibilility than COMm (peak2), as the flexibility reduces because also this loop is in contact with the 227G 
making  hydrogen  bond having  occupancy  more   than  46  %,  whereas   this   interaction   is  never  present   in 
COMPm. In any event, this region is far away from the active site, so we focused out attention on the loop  
containing   residues   only   on   linker,   because   this   region   has   been   found   to   adopt   several   different 
conformations in previous structure, and its mobility appears to be correlated with RdRP catalytic activity.  
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N-terminal (resid 32-42)
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remains  stable  during   the  course  of   the   trajectory,   showing  an  average  RMSD below 1.7    while  on   theǺ  
contrary, the rest three system viz APO, APOm and COMm showed varying level of periodicity(figure9 (B). 
In case of APO, the system was found to oscillate around an average value of 8.3A. At first, around 5ns the  























the   periodicity   is   larger,  with   roughly   one   oscillation   between   4.5   Å   and   18  Å,   as   confirmed   from   the 
distribution  having  the   largest  peak  at  ~13  Å.  This   results  are  consistent  with   those  in  Figure8   in  RMSF, 
indicating a larger flexibility of the linker region in APOm with respect to APO. 































































APO APOm COMPLEX COMPLEXm
Motif-I & close residue Motif-II
The  N­Terminal   domain  along  with   a   long   insert   in   the   finger   domain   constitutes   the   fingertip   region. 
Fingertip   is   important  not  only   for   the   translocation  of   the   template  but  also  as   it   contains   two  highly  
conserved motifs motif I, which , and motif II, [10,12,49]. Previous studies by Choi and Nytes   have reported 
resistant mutations for different classes of NNIs to lie in (E291G) and close to (F224S/Y) Motif II. The resistant 
mutation   I261M   against   227G   is   found   to   lie   in   the  Motif   I   of   the   fingertip   region.   It   was   previously  
hypothesized that the linker of fingertip region is involved in protein dimerization and also provides a binding  





























process   of   polymerization.   This   residue   might   be   involved   in   the   interaction   with   template   during 
polymerization as its location is close to the template entrance site. 
The mutation from I261 to M261 is a change of small(S) amino acid to large (L) amino acid, as methionine has 
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Figure11:     Electrostatic potential maps of the 227G binding pockets of RdRp: (A) COM(I261); (B) COMm (M261) surface (positive in  
blue, negative in red, and neutral in white). 227G  is shown in stick and colored according to the atomic­coloring scheme (C in silver , O in  
red, and N in cyan and Sulfur in yellow). 









moves   from  its   original   position   and   relocate   itself   into   a  new  position   of   the   same  binding   site[figure  





















































































and drug resistance of  227G.   the docking pose  in COM was stable  and conserved through out  the entire 








Apart   from  these   two  major  concern   it   could  be  very  much  probability   the  binding  of  227G hinder   the 
dimerazition,  as   it,   itself  bind  on   the   surface  and   secondary   it   attracts   the   linker   region   towards  cavity.  
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When   the   Ile261   to   Met261   residues   are   mutated   in   RdRp­227G   complexes   introduce   a   functional 
confirmation in the loops, fingertip and N­terminal region. Although there is not as such remarkable changes 

































































which   achieved   a   rigid   configuration   after   binding   of   the   227G   in   contrast   to   its   flexible   behavior. 
Simultaneously other loops apart from linker comes closer towards binding site making interaction with 227G 
and inducing a contraction into the entrance of the template site, led a complete closer of this tunnel.










chunnel   analysis   [106]   on   COM   and   COMm,   to   identify   the   functionally   important   tunnels   reported 
experimentaly such as template entrance channel, NTP entrance channel and the exit channel from the C­
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Abstract
The impressive progress in computational techniques applied to biologically and pharma-
cologically inspired problems is facing the challenging task of extending even more the range
and the complexity of the questions that should be addressed. A single technique may not be
well suited to shade light on a specific problem and the combination of different computational
approaches will provide the appropriate answer. The example of such combined strategy is dis-
cussed in the present paper in relation to the inhibition of replication in Bovine Viral Diarrheal
Virus (BVDV), a member of the Flaviviridae family that contains also the Hepatitis C Virus
(HCV). In a previous work, a promising inhibitor (227G) targeting the virally encoded RNA-
dependent RNA polymerase (RdRp) of both BVDV and HCV was identified by combining
biological assays and computer simulations, and the effects of a resistant mutation (I261M)
was identified. In the present work we applied several biophysical computational approaches,




ranging from MM/PBSA to metadynamics to provide a more quantitative understanding of
the inhibition action and of the resistance mechanism developed by the virus after the I261M
mutation. We calculated the free energy of binding of 227G and characterized its dissociation
from the wild-type and mutated RdRps of BVDV in order to provide an estimate of binding
residence times, which are related to activity. The evaluated free energies of binding agree well
with the experimentally derived value, confirming the validity of the approach. The biophysi-
cal picture of the inhibition action and the quantitatively results obtained in this study may be
of support in defining an efficient strategy to design new, more potent and selective antivirals.
Introduction
Understanding ligand-protein interaction processes is crucial for modern drug discovery process,
which is often fraught with critical junctures at which decisions are difficult and a molecular knowl-
edge is crucial to gain the upper hand thereon. Computational approaches can play an important
role in this challenging task. This role can thrive even more if different computational approaches
from bioinformatics to state-of-the-art molecular simulations at the desired level of accuracy are
combined properly. Models (if properly validated) may provide insights in the details of the pro-
cesses, allowing to access features often difficult to be observed experimentally. In the absence
of experimental data, structural models can be built and represent the starting point of simulations
that have the double functions of gaining insights in the details of the processes and of validating
the models. Computational molecular biology approaches are keys to face this challenge, provid-
ing a way to effectively bridge the gap between the time and size scales reachable by theoretical
methods and those biologically relevant.
An application of this combined strategy based on different computational approaches, of
which the appropriate interplay is a challenging and delicate issue itself, is represented by the
study of the action of antiviral compounds. In particular, our attention focused on the inhibition
action of 227G (see Figure 1a, where also the numbering of the atoms is reported), which has
been demonstrated to be promisingly active against both Hepatits C Virus (HCV) and Bovine Vi-
2
ral Diarrheal Virus (BVDV) belonging to the Flaviviridae family. HCV and BVDV have created
havoc by effecting Human race directly or indirectly. HCV (officially recognized as the silent epi-
demic) infected approximately 180 million people worldwide, and it is the leading reason for liver
transplantation in the United States.1,2 It creates a significant burden to health-care systems at-
tributable to mortality (250,000 deaths can be attributed to HCV each year in the world), morbidity
and treatment costs.1,3,4 Unfortunately, more than 20 years after discovery of HCV5 therapeutic
options remain limited. No vaccine or effective therapy broadly targeting all genotypes of HCV6
is disposable at present. Antiviral treatment is unlikely to induce significant population-wide re-
ductions, and mortality is expected to continue to increase, at least in the next 10-20 years. BVDV
causes a range of clinical manifestations in cattles,7 thereby continuing to be a financial burden
to the farming industry. In fact, diseases related to BVDV cause decreased performance, loss of
milk production, reproductive wastage, and increased risk of morbidity and mortality. It is the
most costly viral disease in US cattle herds, with losses estimated at $2 billion dollars per year.
Analogously to HCV, an appropriate treatment of BVDV infections is still far from having been
developed.8 Thus there is a call for highly effective and selective inhibitors of HCV and BVDV
replication to develop improved therapeutic options and to keep the upper hand on viral infections.
The major efforts to develop Flaviviridae-directed antiviral agents have focused on the inhi-
bition of essential virally-encoded enzymes such as viral polymerases, following the successful
paradigm established for HIV, for which inhibitors of the reverse transcriptase have reached clini-
cal use.9,10 The Flaviviridae NS5B RNA-dependent RNA polymerase (RdRp) is considered one of
the most interesting targets, since polymerase activity is essential for viral replication, and mam-
malian host cells are devoid of such RdRp, thus offering the opportunity to identify very selective
inhibitors of the viral enzyme.11 The structure of BVDV RdRp is shown in Figure 1b, with the
important regions highlighted in different colors.
In the search of antivirals, the benzimidazole class of compounds has been extensively pursued
as potent inhibitors12–15 Among them we identified a promising candidate, 227G, which appears
powerful in inhibiting BVDV RdRp.16,17 In the present paper we deepen the analysis of 227Gs’
3
Figure 1: (a) Ball and stick representation of 227G with oxygen atoms in red, nitrogen atoms in
blue, carbon atoms in cyan, sulfur atom in yellow, and hydrogen atoms in white. (b) Cartoon
representation of BVDV RdRp. Different domains of RdRp are differently colored: thumb in
green, finger in blue, palm in red, and the unique N-terminal in magenta.
4
action on wild type and resistant mutated BVDV RdRps via a thorough application of different
computational approaches, ranging from standard molecular dynamics (MD) simulations, metady-
namics, and molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) calculations. The
I261M mutated RdRp has been proven to mantain its functionality also in the presence of 227G,
making the inhibitor useless. Our study on the wild type and mutated RdRps identified the key
residues involved in the action mechanism and in the resistance development by mapping the in-
teractions during the unbinding process of 227G from the RdRps. Our hypotheses are conforted
by the good agreement of computational results with the experimentally available data. In conclu-
sion, this study allowed not only to identify additional determinants of 227G action, but also to
validate a computational protocol that might be very powerful in supporting a more efficient and
structure-based drug design.
Results and discussion
The computational approaches we used in the present work aim at providing different and comple-
mentary answers to the problem of 227G action. While well suited to simulate a rare event such
the dissociation process of 227G from RdRp and to furnish the values of the associated activation
barriers, metadynamics is not always a convenient tool to evaluate the binding free energy. This is
due to the fact that the calculation of this latter quantity requires the evaluation of the association
process, for which the reaction coordinates chosen to investigate the unbinding might be inappro-
priate and unable to provide a good converged free energy. Thus, we estimated the binding free
energy by performing MM/PBSA calculations.
Unbinding of the compound: use of metadynamics
To quantitatively assess the different behaviour of 227G bound to the wild type and I261-mutated
BVDV RdRps (hereafter COMPLEX and COMPLEXm, respectively) we performed metadynam-
ics simulations of the unbinding process of the compound from the two proteins (see Materials
5
and Methods for more details on metadynamics). By accelerating the dynamics of the collective
coordinates that describe the unbinding process, i.e., the distance between the centers of mass of
227 and of the binding pocket (dcom) and the number of hydrophobic contacts (nhph), it is possible
to catch the essential features of a process otherwise unaccessible by standard MD simulations.
The different paths followed by 227G by leaving COMPLEX and COMPLEXm are visualized in
Figure 2a and b. Remarkable is the behaviour of the loops and its correlation with the unbinding of
227G, which is correlated to the different initial packing of the compound in the two complexes.
Indeed, only in COM the ligand is covered by the loops, in particular the linker L4. Therefore, it
is consistent that the dissociation of 227G is accompanied to a significant displacement of L4 (see
upper and lower panels of Figure 2a). At opposite, the path of 227G to escape from the mutated
RdRp goes aside of the linker, and is not accompanied by any significant movement of the linker
but only by fluctuations.
Beside the qualitative picture of the unbinding process, from the metadynamics runs the free
energy underlying the process can be extracted in function of the accelerated coordinates. For
COMPLEX and COMPLEXm the free energy surfaces (FESs) extracted from the simulations are
shown in Figure 3 and Figure 4. The FES associated with the undocking from COMPLEX (Fig-
ure 3) presents two minima: the deepest one (1 in Figure 3) corresponds to the initial orientation
identified in a previous work of us.17 In this initial position 227G points its benzyl group toward
the template entrance gate of the polymerase and is stabilized in the cavity by a strong hydrogen
bond (HB) formed by the atom N2 of azole moiety with the residue Asp126, which lyes in the
linker. During the standard MD simulations this HB is present for more than 95% of the simula-
tion. A second HB appears between the atom N5 of 227G and the side chain oxygen of Ser533 and
is observed for more than 50% of the time. Additionally, several hydrophobic (HpH) contacts con-
tribute to the stabilization of 227G in this minimum. In particular, HpH contacts involve Pro262,
Ile261, Arg127, Glu128, Arg132, Gly220, Ala221, and Tyr289. Leaving this stable position in
the binding pocket requires 227G to overcome an energy barrier of ∼12kcal/mol. The departure
from Minimum 1 starts with the disruption of the Hbond connecting 227G to Asp126. As a conse-
6
Figure 2: Evolution of the center of mass of 227G in (a) COMPLEX and (b) COMPLEXm during
the metadynamics simulations of the undocking process. In the upper panels the whole system
(in ghost) is represented, while in the lower panels only 227G and the relevant loops are shown.
Loops and 227G are represented in a time-step-coloring fashion, which colors differently the con-
figurations at different steps: initial states in red, half-trajectory states in white, and final states
in blue. The arrows in the lower panels highlight the exit paths of 227G from COMPLEX and
COMPLEXm. Pictures were made with VMD.18
7
Figure 3: Free energy surfaces as a function of dcom and nhph for the unbinding of 227G from
COMPLEX. Isosurfaces are drawn one per 1 kcal/mol. Insets show Ligplot of snapshots of 227G
in the minima extracted from the metadynamics runs.
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Figure 4: Same as Figure 3 for the unbinding of 227G from COMPLEXm.
quence, 227G moves slightly deeper into the cavity with a small rotation of the azole moiety around
the compounds’ major axis. The displacement brings the N2 atom of 227G closer to the residue
Pro262 of Motif I and a HB is established between them. The next step involves the breaking of
the HB between N5:227G and Ser533:O, this latter a residue of loop L3. As a consequence the tail
of 227G acquires mobility and the compound rearranges itself coming closer to Loop L2 with the
formation of a new HB, Asn217:ND2 @S1:227G. Successively, the unbinding proceeds and the
two HBs bonds, Asn217:ND2 @S1:227G and Pro262:O@N2:227G, are disrupted. This causes a
slight jump of the 227G toward the mouth of the cavity, which is flanked mainly by Arg127 of loop
L4, Ala392 of Loop L1 and Phe224 of Loop L2. Due to the movement of 227G an opening of the
entrance starts as Arg127 of Loop L4 moves away from Loop L1.
227G moves further upwards and lies mainly between Loops L4, L2 and L1. At this stage
the tail of 227G is held by two HBs with residues Pro262 of Motif I and Arg132 of Loop L4. A
second, very shallow minimum (2 in Figure 3) is reached by 227G along the unbinding route at
9
dcom ∼ 34 Å and nhph between 5 and 7. In Minimum 2 the major stabilizing contributions in form
of HpH contacts are essentially lost with the exception of that involving Glu128. Additionally,
two weak Hbonds with residues Pro262 and Asn264 belonging to Motif I are present. The role
of Minimum 2 in the unbinding process needs further analysis. Indeed, Minimum 2 might act as
an intermediate along the escape route, from which 227G has an equal probability to definitely
dissociate or to re-associate, being the free energy barrier for both processes ∼ 5 kcal/mol.
As shown in Figure 4, the topology of the FES for COMPLEXm is different from that of
COMPLEX, as three pronounced minima are clearly recognizable. The first one (Minimum 1
in Figure 4) is the stable position in which 227G were found after a docking study and standard
MD simulations. Note that here 227G has its sulfur atom directed toward the template entrance
gate, assuming an orientation opposite to that characterizing the deepest minimum found in the
wild type polymerase. In Minimum 1 227G is stabilized by strong HpH contacts with Met261,
Ile287, and Try289. Additional HpH contacts are provided by Gly223 and Tyr674. 227G positions
itself in between Loops L1 and L2. A small barrier of ∼ 2 kcal/mol separates Minimum 1 to
a second basin, Minimum 2, where 227G interacts essentially via HpH contacts with residues
Ala221, Gly223, Phe224, Met261, Arg295, and Gly406 belonging to Loop L2 and Motif I. A
short-life HB connects residue Tyr289 and the azole moiety of 227G. This HB is soon disrupted
and the tail of 227G starts interacting with Glu128 of loop L4. From Minimum 2, 227G reaches
another intermediate state, Minimum 3, with a free energy cost of ∼ 5 kcal/mol. In this minimum
the major contribution to the stabilization of 227G comes from Met261, Asn264, Tyr289, and
Ser532, which are residues of Loop L3 and Motif I, in form of HpH contacts. From Minimum
3 a barrier of ∼ 4 kcal/mol separates 227G from the aqueous environment. Before reaching the
solvent 227G keeps a weak linkage to the protein by interacting with the residues of the hood of
the N-terminal (residues Val92 to Ser122 ).
Comparing the two FESs, it immediately appears that the deepest minimum in COMPLEX is
more pronounced than in COMPLEXm. Additionally, the free energy barriers are also larger in
COMPLEX than in COMPLEXm, assessing an enhanced stability of 227G in the wild type RdRp
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than in the mutated polymerase. In particular, the largest barrier along the escape route is ∼ 7
kcal/mol smaller than in COMPLEX.
To gain a more quantitative assessment of the stabilization in COMPLEX and COMPLEXm we
evaluated the interaction energies of the compound with the relevant residues within the framework
of the Amber force-field description. The results are reported in Figure 5. Note the large reduction
in the interaction with residue Asp126 (which has the most stabilizing interaction with 227G in
COM) when the mutation occurs. This is consistent with the different position of the linker in the
two complexes, as Asp126 belongs to this loop, which is approaching very closely 227G in COM.
This structural arrangement of L4 has the double effect of stabilizing 227G and of reducing the
space available to the template RNA strand to enter the polymerization site. In COMm the loop L4
undergoes more pronounced fluctuations and on average it is not able to approach and to interact
with 227G. Such a lack of interaction would probably leave enough space for the entrance of the
RNA template in the polymerase an consequently for the functioning of the system.




The energy barriers required to leave the binding sites in COMPLEX and COMPLEXm offer a
first quantitative (although approximated) indication of the different activity of 227G in the wild
type and mutated RdRp. However, a validation of the results obtained in the present work needs
a more close comparison with the available data coming from biological assays. To achieve this
goal we evaluated the so-called half maximal inhibitory concentration (IC50), a measure of the
effectiveness of a compound in inhibiting biological or biochemical function. IC50 can be related
to the binding free energy ∆Gbind by the following equation:19,20
∆Gbind = RTlnIC50, (1)
where R is the universal gas constant and T the temperature. To calculate ∆Gbind we used the
Table 1: Calculated values of the contributions to ∆Gbind in kcal/mol. The experimental value
reported for comparison is extracted from measured IC50 16 by using Equation Eq. (1) at T = 298
K. The third column contains for each term the difference between the values of COMPLEX and
COMPLEXm.
COMPLEX COMPLEXm ∆(COMPLEX-COMPLEXm)
∆Eelectrostatic -36.0 (± 1.9) -42.9 (± 2.7) 6.9
∆EvanderWaals -52.2 (± 2.9) -39.9 (± 1.8) -12.3
∆GPB -24.1 (± 2.7) -13.7 (± 3.2) - 10.4
∆GNP -5.8 (± 1.2) -5.6 (± 0.9) -0.2
PBtot -33.9 (± 3.1) -29.8 (± 3.4) - 4.1
∆Gelectrostatic+PB -11.9 (± 3.9) -29.2 (± 2.6) 17.3
∆GvanderWaals+NP -57.9 (± 4.7) -45.6 (± 3.8) -12.3
TSsolute -18.9 (± 2.3) -17.6 (± 1.8) -1.3
∆H -69.8 -74.8 5.0
∆Gbinding -14.0 -12.2 -1.8
Experiment
∆Gbinding -12.0 not available
MM/PBSA method21–23 that allows ∆Gbind to be dissected in the single contributions within the
framework of the Amber force-field. The results for COMPLEX and COMPLEXm are listed in
Table 1. The binding free energy for COMPLEX was found to be -14.0 kcal/mol. The binding free
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energy obtained from experimental IC50 value by inverting Equation Eq. (1) was -12.0 kcal/mol,
which was in good agreement with the result extracted from the MM/PBSA calculation and with
the largest energy barrier extracted from the metadynamics simulations. Following the same pro-
cedure, we calculated the binding free energy of 227G in COMPLEXm which came out to be -12.2
kcal/mol.
Hydration of the compound along dissociation path
An important role in the drug-target interaction, and more in general in the ligand-protein inter-
action, is played by the solvent.23–27 A way to characterize this contribution is to evaluate the
first shell of water molecules surrounding the 227G in COMPLEX and COMPLEXm during the
simulations. The calculated probability distributions of the water population in this first shell are
Figure 6: Histogram of number of water molecules around the drug during the simulation in COM-
PLEX and COMPLEXm system represented by green and cyan, respectively.
reported in Figure 6. In green are represented the data related to COMPLEX while in cyan those
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obtained for COMPLEXm. Remarkable differences are present. With respect to COMPLEX the
distribution for COMPLEXm is shifted toward larger numbers of water molecules around 227G.
In fact, the average number of waters ringing the inhibitor is ∼ 6 in the case of COMPLEX and
∼ 10 in COMPLEXm. Thus, the compound is more exposed to the solvent in the mutated RdRp
than in the wild type, indicating a cavity more open to the aqueous environment in the former than
in the latter system. The interaction of the inhibitor with Loop L4 present in COMPLEX but not
in COMPLEXm is probably responsible for the hindered access of water to the cavity. A further
confirm of the different exposure to the solvent in COMPLEX and COMPLEXm comes from the
calculation of the solvent accessible surface area (SASA) for the two adducts by Platinum.28 The
binding pocket in COMPLEX results more hydrophobic than in COMPLEXm.
Conclusions
To develop more efficient antiviral agents a more detailed microscopic knowledge of the features
determining mechanism of action and stability of compounds is necessary. A structure-based drug
design has to include structural features at large, intending with this dynamical effects and interac-
tion with the solvent. In the present work, we applied to the problem of an inhibitor, 227G, acting
on the wild type and mutated BVDV RdRp, a computational strategy that accounts for all these
effects in an all-atoms description. By studying the undocking mechanism we were able to accom-
plish an inventory of the interactions between 227G and the various residues of RdRp. At the same
level of accuracy, the hydration of the system along the dissociation route was evaluated pointing
out the different degree of hydration in the wild type and mutated RdRps. Finally, we estimated
the protein ligand binding free energy, which came out in good accordance with the binding free
energy extracted from the available experimentally determined IC50. Such agreement represents
a first validation of a computational protocol that can be used to provide hints and suggestions for
the rational drug design mentioned above.
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Materials and Methods
Standard MD and Metadynamics
Initial relaxation of the systems of COMPLEX and COMPLEXm was performed for 30ns at con-
stant volume and temperature using the MD software package ORAC.29 The process of undocking,
a rare event, which can not be reached by standard MD simulations with an all-atom representa-
tion. The metadynamics algorithm30 is based on a history dependent biasing potential added in a
subspace defined by a chosen set of reaction coordinates sα(x), aimed at reconstructing the multi-
dimensional free energy of a given process. At time t the biasing potential VG is given as the sum
of repulsive Gaussian functions added with a frequency 1/τG:




2(δ s)2 , (2)
where W is the Gaussian height, δ s the Gaussian width. Due to this potential, the system is
discouraged from revisiting the configurations already sampled. Metadynamics not only allows
the acceleration of rare events, but also the reconstruction of the free energy FG(s, t) =−VG, which
is an approximation of F(s) in the region Σ(s) explored by s(xG(t)) up to time t.31,32 The accuracy
of free energy reconstruction is dependent upon the Gaussian parameters W , δ s, and τG. Details
of the metadynamics algorithm have been previously described.30,31,33
The choice of reaction coordinates (RCs) is pivotal to obtain the best approximation of the free
energy. The RCs used here to describe COMPLEX and COMPLEXm dissociation are:
1. The distance dcom between the center of mass of the ligand and the center of the mass of the
protein. A similar choice of RCs has been applied e.g. in Ref.34
2. The number of hydrophobic contacts nhph between non polar carbons on the ligand and on






1− (ri j/r0)b , (3)
where ri j is the distance between the atoms of interest, a and b have values of 6 and 12,
respectively, and r0 = 6 accounts for the typical carbon-carbon distance (4/4.5 Å) and the
thermal motionsÕ amplitude (1.5/2 Å). A similar RC has been used e.g. in Refs.27,35,36
The Gaussian parameters were W = 0.25 kj/mol, δ sdcom =0.5 Å, and δ snhph =6 in both the case of
COMPLEX and COMPLEXm. The time interval between two successive Gaussian depositions
was set to 0.5 ps in all the simulations.
Free energies surfaces were calculated as a function of (dcom,nhph). On COMPLEX and COM-
PLEXm we performed 22ns-long and 12ns-long metadynamics runs, respectively. The activation
free energies associated to the detachments were extracted by stopping the summation over Gaus-
sians just after the complete detachment of the drug.27,34
MM/PBSA Calculation
Since the minimum energy pose obtained from metadynamics corresponded to the initial docking
position, MM/PBSA calculations were performed from the snapshots taken from the 30ns-long
standard MD simulations of the initial docking pose in both COMPLEX and COMPLEXm. Ac-
cording to the MM/PBSA method binding free energy (∆Gbind) of each system could be conceptu-
ally summarized as follows
∆Gbind = Gcom− (Grec+Glig). (4)
Here Gcom,Grec, and Glig the free energy for the RdRp-inhibitor complex, receptor (RdRp), and
ligand (inhibitor), respectively. Each term is calculated by averaging for each system the following
free energy energy ∆G = ∆EMM+∆Gsolv−T∆S, where ∆EMM refers to the molecular mechanics
energy, ∆Gsolv to the solvation free energy, and T∆S to the vibrational entropy and are calculated
as follows:
∆EMM = ∆Ebond+∆Eangle+∆Etorsion+∆Evdw+∆Eelect , (5)
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∆Gsolv = ∆GPB+∆GSA, (6)
∆GSA = γSA+b. (7)
EMM includes the average molecular mechanics energy contributed by bonded (Ebond,Eangle, and
Etorsion) and nonbonded (Evdw and Eelect) terms of the force field. Here EMM was further decom-
posed in the individual nonbonded contributions from residues belonging to the binding pocket.37
∆Gsolv is the solvation free energy, which is due to polar (∆GPB, evaluated using the Poisson-
Boltzmann equation) and nonpolar (∆GSA, proportional to the surface area38) terms. The elec-
trostatic solvation free energy was calculated using DELPHI39,40 software, with low dielectric
medium for solute (ε=1) and high dielectric medium for solvent (ε=80). Atomic radii were taken
from PARSE38 with an additional value of 1.90 Å for phosphorus,41 and in order to be consistent
with molecular mechanics energy calculation, the partial charges on solute were taken from the
Amber 99 (RNA) force field. An 80% boxfill lattice with grid spacing 0.5 grid/Å was applied,
and 10,000 linear iteration steps were required to obtain energy convergence. The nonpolar con-
tribution to solvation free energy was determined from Equation Eq. (7), where the surface area
was calculated using MOLSURF,42 and γ and b are 0.00542 kcal/mol Å2 and 0.92 kcal/mol, re-
spectively, for use with PARSE atomic radii.38 The solvent probe radius was set to 1.4 Å. Residues
within 25 Å from the mass center of ligand were used for PBSA calculation. This included the
ligand and water molecules located within 5 Å from the drug.37
The solute entropy contribution (−T∆S) was estimated by normal-mode analysis21 using the
NMODE module in AMBER 9.0. Each of the complex, receptor, and ligand systems were first
minimized before switching over for normal-mode analysis, using a distance dependent dielectric
constant of ε = 4r with r interatomic distance, in the absence of solvent to mimic solvent screen-
ing43 until the convergence criteria of 0.0001 kcal/molÅ was achieved. Normal mode calculation
was extremely time-consuming and computationally expensive; therefore, only residues within 10
Å from the inhibitor center of mass (including water molecules and ions) were used here.37 As
discussed in Refs. 44 and 45 the differences of the calculated entropy value is quite small for dif-
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ferent conformations, and normal-mode analysis calculation usually gave an inaccurate estimation
for solute entropies, thus giving merely qualitative estimates of the solute entropy.46 Therefore,
our calculation was only based on the average entropy value obtained from 100 snapshots taken
from the final 20 ns of MD trajectories with a time interval of 0.2 ns.
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The  present  calculations  provide   a   validation  of   the   combination  of  docking,  MD as   a  powerful   tool   in 






Projected as   the   third   leading cause  of  death,  by   the  year  2030,  Human  immunodeficiency  virus   reverse 
transcriptase(RT)   inhibition has  become a  major  cause of  concern worldwide  .[1]  One  in  155 adults  and 
adolescents are infected with human immunodeficiency virus (HIV) globally, with an astonishing rate of one 
in 21 in Sub­Saharan Africa.[2] In the USA alone, more than half a million people were living with HIV in 2007,  




















approval of AZT in 1987 and followed by didanosine (ddI),  zalcitabine (ddC), stavudine (d4T),  lamivudine  










activation and efficacy depend on the metabolic  state  of   the  infected host  cells.    Given the properties  of  






have  demonstrated  that  NNRTI  binding to  HIV­1  RT  induces  short­range and  long range  conformational  
changes, in enzyme structure. Whereas the ddN analogues (i.e.,  AZT, ddI, etc.),  following their intracellular 








NNRTI  can  be   further  classified   into   'FIRST generation'  and   'SECOND generation'  compounds.   the  First 






and evolve drug escape viral/RT mutants   that  can replicate   in   the presence of  drug(s)   (i.e.   they are drug 
resistant). The 'second generation ' refers to compounds with improved activity spectrum against the most 
common NNRTI­resistant  HIV   variants  which  were  developed  based  on  approach   that   involved   the   the 
concurrent study of several different parameters, as opposed to focusing on potency against wild­type virus, 
approach including: searching for new and/or further evolved chemical scaffolds that allow more ﬂexible and 



















inactive   conformation,   reminiscent   of   the   conformation   observed   in   the   inactive   P51   subunit.Our 
understanding of the molecular basis of RT function asymptotically increased after x­ray elucidation of RT 
structures   in  multiple   forms,   Apo   (without   any   ligand),  Holo   (complexed  with  NNRTI[31,32])   and  other 
complexes (  nucleic acid template primers,[33,34]) , have provided an in depth understanding, and explores  
variability of   RT at atomic level. RT is a heterodimer consisting of two two subunits of 66kDa(p66) and 51  





polymerase active  site   [42­46].  As  a   result  of  NNRTI  binding,  certain  RT domains    actively  participate   in 



















































representation  of   the  chosen  binding  mode and   the  key   residues   involved   in  docking   for  all   four  DABO 
compounds are present in Fig.1B. The RMSD of the MC1332, MC1195 and MC1345 with respect to the lead 




The starting structures  obtained from docking where then used for   further  MD simulation runs  for  20ns.  
DABO  compounds   accommodated   themselves     in   the  hydrophobic   cavity   present   in   the  palm  domain, 










described   in  material   and  method.  Fig   4b)   summarizes   the   favorable  hydrophobic   as  well   electrostatics 
interactions between MC1220, MC1346, MC1332 and MC1195 and the binding pocket respectively which were 
analyzed to identify residues that are important for binding. 





Other residues which make favorable  VdW interactions  in MC1220,  MC1332 and MC1195  include Lys103, 
Val106, Trp229, Leu234, Trp328 and Pro236. This shows that binding is clearly favired by VdW interactions with 
these residues.   
Despite of the cavity being predominantly HpH in nature   the NNI pocket provides   ample   possibilities for  
polar interactions as well. Here again, remarkable contribution is provided by Leu101 with electrostatic energy 




residue  which  contribute   favorably   in  all   the   four  DABO compounds   is  Lys103  with  energy   ­8  kcal/mol, 











mutation relate  well  with the residues contributing the most   in  terms of  electrostatic  and Van Der Waals  
energies   identified by our simulations.  Lys103,  Lys101 and Leu100   were here found to have either highly 
favorable electrostatic or VdW interaction with the inhibitors, indicating their importance for the tight binding 






Figure3:  A)  Pictorial   representation   of   ligand­residue   interaction   spectrum   of   key   residues   of  NNRTI   binding   site  with  DABO 
compounds. The residues are represented in stick while the HB are depicted in magenta color spirals.  B) Ligand­residue interaction  







Figure4:  A)  Pictorial   representation   of   ligand­residue   interaction   spectrum   of   key   residues   of  NNRTI   binding   site  with  DABO 
compounds. The residues are represented in stick while the HB are depicted in magenta color spirals.  B) Ligand­residue interaction  




we did  a  comparative  analysis  of  our  DABO compounds  with    previously   reported  NNRTI  bound crystal  
structures of structurally related HEPT[53,54] and derivatives of 6­Benzyl­1­(ethoxymethyl)­5­isopropyluracil, 
MKC­442[55,57], in order to characterize similarities and differences in binding of these related   classes of  





the loops occupy positions similar to  those     of  the unliganded enzyme.[56] but  in the presence of MKC­
442[55],     the   loops  move,   contracting   the  binding  pocket   and   tracking   the   shorter   ethoxymethyl   tail.   In  
accordance with the behavior exhibited by HEPT,  we observed that DABO compounds exhibited slight change 











The hydrophobic  nature of   the NNI pocket  provides relatively   few possibilities   for  polar   interactions and 

























Structure­activity   relationship   (SAR)   studies  show that  a  5­position  substituent  on   the  pyrimidine   ring   is  
essential for DABO analogues to bind to RT. As previously reported in HEPT compounds the same trend we 
observed in our DABO compounds. In HEPT compounds, replacement of the 5­methyl (position X in table1)  











make   difference   in  MKC­442,   GCA­186   and  MC1220.   the   C6   substituents   are   positioned   in   the   upper 
subpocket of the NNRTI binding site, which is formed between Leu100, Tyr181, Tyr188, Phe227 and Trp229.  
This region has methyl group in other analogs of MC1220, except MC1195 where it substituted with hydrogen. 












Compd X Y aEC50 b, cLong term 
activity
    DABO 1332 CH2CH3 CH3 0.01 no (>100 µM)
DABO 1195 CH3 H 0.09 no (>100 µM)
DABO 1346 H CH3 0.00
yes (100 µM)











































acid  clamp we sampled  the    minimum distances  between  the  residues  of   the   thumb domain  and  finger 

































probable  distortions  of   residues  near   to   the  polymerase  active   site  which  may  effect   the  polymerization  
process. MC1220 accommodates itself in such a way that it is flanked on both side by two beta sheets. these  
beta  sheets  harbor   two  important  conserved   structural   features  of  HIV rt  which   include   the  Primer  grip  
region(Met230 and Gly231), guide the correct positioning of the 3'end of the primer and  catalytic triad(YMDD 
motif)   which   is   involved   in   addition   of   nucleotide   to   the   growing   primer   chain.  Here   also,   we   did   a 











Fig.7: Minimum distances  between  two beta  sheets  of   the NNRTI binding site  which  harbors   two  important  conserved structural 
features of HIVRT, the Primer grip and catalytic triad(YMDD motif). A) Normalized histogram of the distances are repersented. The red  
and purple dotted line indicate the minimum distances between  the beta sheets in  1DLO( without substrate) and 1RTD (with substrate) 















conformational  dynamics  of  RT   such  that   it   inhibits  DNA polymerization.  Focusing  on   the  catalytic  p66 
subunit, we did a computed minimum distance between thumb and finger domain. The distribution of the  











to   the catalytic  site  and,  consequently,  a  catalytically   incompetent  constellation of   these key  protein  and 
nucleic acid atoms. Thus, by our simulation we were able to hypothesize that widening of distance between 







To explore the residence time and the escape mechanism of  MC1220 and its  analogs “rare events” a well  
validated  Metadynamics,   is   in   progress   for   future   computational   studies   of   RT.  This  would   allow  us   to 
efficiently study the effect of a range of NNRTIs on the opening/closing motion of the p66 polymerase region, 
in isolation from other degrees of freedom. In particular, it could be used to predict the potency of NNRTIs and 
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on   ligand   binding,   to   understand   the  molecular   basis   of   drug   interaction,   to   shed   light   on   probable 
mechanism of inhibition and resistance, to understand the effect of mutation on the dynamics of protein, to  
































































mechanical   obstruction   to   local   conformational   changes   taking   place   in   the   catalytic   site   leading   to  
impairment of polymerization. Through our simulations we observe that binding of NNRTI into the binding 
pocket   resulted   into  a   local   conformational  change  within   the  binding  pocket,  by  widening   the  distance 
between two beta sheets , necessary for correct positioning of 3' end of the template. Thus, by our simulation 
we were able to hypothesize that widening of distance between the thumb­finger domain leads to a 'hyper  
open' of HIV­RT which along with the distortions produced in the residues at the active site may result into  
inhibition of DABO bound HIV­RT structures.
To sum up, in the current study, we have presented a complete analysis of the effect of resistant mutant   at  
dynamical and energetic level, as well as tried to understand, how the polymerization regained by RdRp in  
mutant protein though drug is present into the cavity. 
It is noteworthy that, due to the resistance mechanism, designing a potent antiviral is a very challenging task .  
In future, we have plan to extend the investigation to understand the resistance mechanism as it is one of the 
tough task in current scenario of drug development pipe line. 
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